[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 10119
1. Akiyama T, Okino T, Konishi H, Wani Y, Notohara K, Tsukayama C, Tsunoda T, Tasaka T, Masaki Y, Sugihara T, Sadahira Y: CD8+, CD56+ (natural killer-like) T-cell lymphoma involving the small intestine with no evidence of enteropathy: clinicopathology and molecular study of five Japanese patients. Pathol Int; 2008 Oct;58(10):626-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD8+, CD56+ (natural killer-like) T-cell lymphoma involving the small intestine with no evidence of enteropathy: clinicopathology and molecular study of five Japanese patients.
  • The present study reports five CD8+, CD56+ (natural killer (NK)-like) T-cell lymphomas involving the small intestine without evidence of enteropathy, from Japan.
  • Three were intestinal T-cell lymphoma.
  • Lymphoma cells of all patients shared the common phenotype: CD3+, CD4-, CD5-, CD8+, CD56+, CD57-, T-cell intracellular antigen-1+, granzyme B+.
  • In contrast to nasal/nasal type NK-cell lymphomas, they had clonal rearrangement of T-cell receptor(TCR) genes and were negative for EBV-encoded RNA.
  • Immunohistochemistry and genetics suggested that three cases were of alpha beta T-cell origin and two cases were of gamma delta T-cell origin.
  • According to the classification based on the recent genetic studies of European enteropathy-type intestinal T-cell lymphoma (ETL), the present cases could be classified as type 2 ETL.
  • [MeSH-major] Antigens, CD56 / immunology. CD8-Positive T-Lymphocytes / immunology. Intestinal Neoplasms / pathology. Intestine, Small / pathology. Killer Cells, Natural / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Clone Cells. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Gene Deletion. Gene Rearrangement, T-Lymphocyte / genetics. Humans. Immunoenzyme Techniques. In Situ Hybridization. Male. Middle Aged. Neoplasm Staging. Prednisolone / therapeutic use. RNA, Viral / analysis. Survival Rate. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801082.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


2. Tsutsumi Y, Kanamori H, Yamato H, Ehira N, Kawamura T, Obara S, Tanaka J, Asaka M, Imamura M, Masauzi N: Lung infiltration of adult T-cell leukemia cells following the administration of arsenic trioxide. Lung infiltration of ATL by AS(2)O(3). Med Hypotheses; 2006;66(1):201-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung infiltration of adult T-cell leukemia cells following the administration of arsenic trioxide. Lung infiltration of ATL by AS(2)O(3).
  • [MeSH-major] Arsenicals / adverse effects. Arsenicals / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration / chemically induced. Lung / pathology. Oxides / adverse effects. Oxides / therapeutic use

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16165312.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Deltaretrovirus Antibodies; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


3. Glasser L, Meloni-Ehrig A, Greaves W, Demel KC, Butera J: Synchronous development of acute myeloid leukemia in recipient and donor after allogeneic bone marrow transplantation: report of a case with comments on donor evaluation. Transfusion; 2009 Mar;49(3):555-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous development of acute myeloid leukemia in recipient and donor after allogeneic bone marrow transplantation: report of a case with comments on donor evaluation.
  • BACKGROUND: A case of donor cell leukemia (DCL) is reported.
  • A 42-year-old female developed acute myeloid leukemia (AML) of donor cell origin 18 months after a bone marrow transplant (BMT) from her brother.
  • The classification of DCL and recommendations for laboratory testing of potential hematopoietic stem cell (HSC) donors are discussed.
  • [MeSH-major] Bone Marrow Transplantation / immunology. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / surgery. Tissue Donors
  • [MeSH-minor] Adult. Chromosomes, Human / genetics. Female. Humans. Immunophenotyping. Karyotyping. Transplantation, Homologous / immunology


Advertisement
4. Klatt T, Ouyang Q, Flad T, Koetter I, Bühring HJ, Kalbacher H, Pawelec G, Müller CA: Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis. J Rheumatol; 2005 Feb;32(2):239-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: RA patients show clonal expansion of dysfunctional, terminally differentiated CD8+ EBV-specific T cells in their T cell responses to immunodominant lytic peptide EBV epitopes, which could be a sign of specific impairment of virus-host interactions in RA.
  • [MeSH-major] Antigens, CD28 / immunology. Arthritis, Rheumatoid / immunology. CD8-Positive T-Lymphocytes / immunology. Cell Proliferation. Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / immunology
  • [MeSH-minor] Adult. Biomarkers / metabolism. Cell Count. Cell Line. Clone Cells. Female. Flow Cytometry. Humans. Interferon-gamma / metabolism. Leukocytes, Mononuclear / immunology. Male. Middle Aged. T-Lymphocyte Subsets / immunology. T-Lymphocyte Subsets / pathology. T-Lymphocyte Subsets / virology


5. Kansal R, Sait SN, Block AW, Ward PM, Kelly FL, Cheney RT, Czuczman M, Brecher ML, Barcos M: Extra copies of chromosome 2 are a recurring aberration in ALK-negative lymphomas with anaplastic morphology. Mod Pathol; 2005 Feb;18(2):235-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied 24 anaplastic large cell lymphomas (ALCL) classified by World Health Organization criteria [17 primary nodal/systemic (10 ALK+, 7 ALK-), seven primary cutaneous], and 17 additional non-Hodgkin's lymphomas [one ALK+ B-lineage lymphoma, 14 ALK- diffuse large B-cell lymphomas (seven anaplastic variants, five nonanaplastic, two secondary CD30+), two follicular lymphomas].
  • ALK- lymphomas with anaplastic morphology showed extra nonrearranged anaplastic lymphoma kinase gene loci (P=0.004) due to trisomy 2 irrespective of the following factors: B or T/null phenotype (P=0.315), diagnostic categories of systemic or cutaneous ALCL or the above-mentioned B-cell lymphomas (P=0.131), and CD30 positivity by immunohistochemistry (P=1.000).
  • Its presence in secondary B-cell lymphomas suggests that trisomy 2 may be a secondary cytogenetic aberration in lymphomas in general.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 2 / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Antigens, CD15 / analysis. Antigens, CD30 / analysis. Child. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Male. Mucin-1 / analysis. Receptor Protein-Tyrosine Kinases. Statistics as Topic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15475930.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30; 0 / Mucin-1; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


6. Aamot HV, Torlakovic EE, Eide MB, Holte H, Heim S: Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic-pathologic-clinical correlations. J Cancer Res Clin Oncol; 2007 Jul;133(7):455-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: One hundred and twelve cases were follicular lymphoma (FL) and 37 were diffuse large B-cell lymphoma (DLBCL).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Disease Progression. Female. Humans. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Middle Aged. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Mar;9(3):161-7 [7515657.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2133-9 [12796378.001]
  • [Cites] Leuk Lymphoma. 2002 May;43(5):1051-6 [12148885.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2977-84 [9531609.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1587-94 [9193357.001]
  • [Cites] Blood. 2003 Feb 1;101(3):1149-54 [12529293.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] N Engl J Med. 1987 Jan 8;316(2):79-84 [3537802.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1258-65 [15126323.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):45-51 [11343778.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):263-8 [10088543.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3905-14 [7579360.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Apr;30(4):375-82 [11241790.001]
  • [Cites] Semin Cancer Biol. 2003 Jun;13(3):191-202 [12959350.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Mar;39(3):195-204 [14732921.001]
  • [Cites] Blood. 2000 Jul 15;96(2):635-9 [10887128.001]
  • [Cites] Histopathology. 2003 Mar;42(3):292-8 [12605649.001]
  • [Cites] Semin Oncol. 2002 Apr;29(2 Suppl 6):2-6 [12040527.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1459-65 [15902285.001]
  • [Cites] N Engl J Med. 1982 Nov 11;307(20):1231-6 [7133054.001]
  • [Cites] Science. 1985 Jun 21;228(4706):1440-3 [3874430.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] J Pathol. 2006 Jun;209(2):258-64 [16583359.001]
  • [Cites] Hematol Oncol. 1983 Apr-Jun;1(2):187-92 [6376315.001]
  • [Cites] Br J Haematol. 2003 Sep;122(5):745-59 [12930384.001]
  • [Cites] Br J Cancer. 2001 Feb;84(4):499-503 [11207045.001]
  • [Cites] Hum Pathol. 2003 Sep;34(9):915-23 [14562288.001]
  • [Cites] Leuk Lymphoma. 2000 Feb;36(5-6):513-23 [10784396.001]
  • [Cites] Blood. 2002 May 15;99(10):3806-12 [11986240.001]
  • [Cites] Science. 1984 Nov 30;226(4678):1097-9 [6093263.001]
  • [Cites] Br J Haematol. 1998 Jun;101(3):487-91 [9633892.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 2:67-71 [7515649.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jun;25(2):123-33 [10337996.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8886-91 [12077300.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1043-9 [8049424.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Cell. 1985 Jul;41(3):899-906 [3924412.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jun;119(2):94-101 [10867142.001]
  • (PMID = 17235551.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


7. Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, Mentens N, Beverloo HB, Pieters R, Speleman F, Odero MD, Bauters M, Froyen G, Marynen P, Vandenberghe P, Wlodarska I, Meijerink JP, Cools J: Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet; 2007 May;39(5):593-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia.
  • We identified a duplication of the MYB oncogene in 8.4% of individuals with T cell acute lymphoblastic leukemia (T-ALL) and in five T-ALL cell lines.
  • The duplication is associated with a threefold increase in MYB expression, and knockdown of MYB expression initiates T cell differentiation.
  • [MeSH-major] Cell Differentiation / genetics. Gene Duplication. Genes, myb / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. T-Lymphocytes / pathology
  • [MeSH-minor] Cell Line, Tumor. Chromosomes, Artificial / genetics. Flow Cytometry. Gene Dosage. Gene Expression Regulation, Neoplastic / genetics. Genetic Testing. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Mutation / genetics. Nucleic Acid Hybridization / genetics. RNA, Small Interfering / genetics. Statistics, Nonparametric


8. Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H, Ohtsu A: Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan. Jpn J Clin Oncol; 2009 Apr;39(4):225-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
  • OBJECTIVE: Prognosis in patients with recurrent or metastatic squamous cell carcinoma of the head and neck is poor, and systemic chemotherapy has an only modest impact on the outcome.
  • Entry criteria included histologically proven squamous cell carcinoma and recurrent or metastatic disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211574.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Odebiyi DO, Adigun OT, Kehinde MO: Effect of sodium salicylate iontophoresis in the management of hip pain in patients with sickle cell disease. Nig Q J Hosp Med; 2007 Apr-Jun;17(2):82-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of sodium salicylate iontophoresis in the management of hip pain in patients with sickle cell disease.
  • OBJECTIVE: The objective of this study was to determine the effectiveness of sodium salicylate iontophoresis in the management of hip pain in patient with sickle cell disorders (SCD).
  • [MeSH-major] Anemia, Sickle Cell / complications. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Arthralgia / drug therapy. Hip Joint / drug effects. Sodium Salicylate / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Iontophoresis. Male. Pain Measurement. Range of Motion, Articular. Treatment Outcome

  • Genetic Alliance. consumer health - Sickle Cell Disease.
  • MedlinePlus Health Information. consumer health - Sickle Cell Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18318099.001).
  • [ISSN] 0189-2657
  • [Journal-full-title] Nigerian quarterly journal of hospital medicine
  • [ISO-abbreviation] Nig Q J Hosp Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; WIQ1H85SYP / Sodium Salicylate
  •  go-up   go-down


10. Kumar M, Meenakshi N, Sundaramurthi JC, Kaur G, Mehra NK, Raja A: Immune response to Mycobacterium tuberculosis specific antigen ESAT-6 among south Indians. Tuberculosis (Edinb); 2010 Jan;90(1):60-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 6-kDa early secreted antigenic target (ESAT-6) is a T-cell antigen recognized by individuals infected with Mycobacterium tuberculosis.
  • [MeSH-minor] Adult. Asian Continental Ancestry Group. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Humans. India / epidemiology. Lymphocyte Activation. Male. Middle Aged

  • Genetic Alliance. consumer health - Tuberculosis.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19944647.001).
  • [ISSN] 1873-281X
  • [Journal-full-title] Tuberculosis (Edinburgh, Scotland)
  • [ISO-abbreviation] Tuberculosis (Edinb)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / ESAT-6 protein, Mycobacterium tuberculosis; 0 / Epitopes; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


11. Karakhanova S, Munder M, Schneider M, Bonyhadi M, Ho AD, Goerner M: Highly efficient expansion of human CD4+CD25+ regulatory T cells for cellular immunotherapy in patients with graft-versus-host disease. J Immunother; 2006 May-Jun;29(3):336-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD4+CD25+ regulatory T cells (T(REG)) are engaged in the regulation of murine and human immune responses as well as graft-versus-host disease (GvHD) after allogeneic stem-cell transplantation.
  • However, we demonstrate that FoxP3 is not a reliable marker for human T(REG) as it is transiently inducible in CD4+CD25- cells upon activation with cytokines or via their T cell receptor.
  • In addition, we successfully expanded CD4+CD25+ cells from patients after allogeneic stem-cell transplantation with or without GvHD and show that different suppressor functions might be lost independently, demonstrating that human T(REG) biology is likely more complicated than previously thought.
  • [MeSH-major] CD4-Positive T-Lymphocytes / cytology. Cell Culture Techniques / methods. Graft vs Host Disease / therapy. Immunotherapy / methods. Receptors, Interleukin-2 / biosynthesis. T-Lymphocytes / metabolism
  • [MeSH-minor] Adult. Antigens, CD28 / biosynthesis. Antigens, CD4 / biosynthesis. Dendritic Cells / cytology. Female. Forkhead Transcription Factors / metabolism. Humans. Male. Middle Aged

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16699377.001).
  • [ISSN] 1524-9557
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD28; 0 / Antigens, CD4; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Receptors, Interleukin-2
  •  go-up   go-down


12. Ibrahim OM, Matsumoto Y, Dogru M, Adan ES, Wakamatsu TH, Goto T, Negishi K, Tsubota K: The efficacy, sensitivity, and specificity of in vivo laser confocal microscopy in the diagnosis of meibomian gland dysfunction. Ophthalmology; 2010 Apr;117(4):665-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the efficacy, sensitivity and specificity of confocal microscopy (CM) parameters: meibomian gland (MG) acinar longest diameter (MGALD), MG acinar shortest diameter (MGASD), inflammatory cell density (ICD), and MG acinar unit density (MGAUD) in the diagnosis of MG dysfunction (MGD).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Count. Female. Fluorescein. Fluorescent Dyes. Humans. Lipids / analysis. Male. Middle Aged. Prospective Studies. ROC Curve. Sensitivity and Specificity. Tears / chemistry. Volatilization

  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • Hazardous Substances Data Bank. FLUORESCEIN .
  • Hazardous Substances Data Bank. D&C Yellow No. 8 .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20189653.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Lipids; TPY09G7XIR / Fluorescein
  •  go-up   go-down


13. Neumann-Haefelin C, Timm J, Spangenberg HC, Wischniowski N, Nazarova N, Kersting N, Roggendorf M, Allen TM, Blum HE, Thimme R: Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology; 2008 Jun;47(6):1824-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection.
  • Virus-specific CD8+ T-cells play an important role in the outcome of acute hepatitis C virus (HCV) infection.
  • In the chronic phase, however, HCV can persist despite the presence of virus-specific T-cell responses.
  • Therefore, we set out to perform a full-breadth analysis of the intrahepatic virus-specific CD8+ T-cell response, its relation to the peripheral T-cell response, and the overall influence of viral escape and the genetic restriction on intrahepatic CD8+ T-cell failure.
  • HCV-specific CD8+ T-cell responses were detectable in most (90%) chronically HCV-infected patients, and two thirds of these responses targeted novel previously undescribed epitopes.
  • [MeSH-minor] Adult. Aged. Alleles. Amino Acid Sequence. Epitopes, T-Lymphocyte / analysis. Epitopes, T-Lymphocyte / immunology. Female. Genotype. HLA Antigens / analysis. HLA Antigens / immunology. HLA-B Antigens / genetics. HLA-B Antigens / immunology. Humans. Interferon-gamma. Liver / metabolism. Liver / pathology. Male. Middle Aged. Molecular Sequence Data. Viral Proteins / analysis. Viral Proteins / immunology

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18454507.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epitopes, T-Lymphocyte; 0 / HLA Antigens; 0 / HLA-B Antigens; 0 / Viral Proteins; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


14. Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB: Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood; 2005 Aug 15;106(4):1175-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic infection with the hepatitis C virus (HCV) is associated with failures of T-cell-mediated immune clearance and with abnormal B-cell growth and activation.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Viral Hepat. 2001 Sep;8(5):341-8 [11555191.001]
  • [Cites] J Virol. 2005 Mar;79(5):3071-83 [15709027.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1755-66 [11748277.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):289-95 [12417585.001]
  • [Cites] J Clin Invest. 2002 Apr;109(8):1011-2 [11956237.001]
  • [Cites] J Clin Invest. 2002 Apr;109(8):1101-10 [11956248.001]
  • [Cites] Clin Lab Haematol. 2002 Dec;24(6):337-41 [12452813.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15669-74 [12441396.001]
  • [Cites] J Hepatol. 2003 Jan;38(1):67-75 [12480562.001]
  • [Cites] J Immunol. 1999 Dec 1;163(11):6236-43 [10570316.001]
  • [Cites] Am J Med. 1999 Dec 27;107(6B):49S-52S [10653457.001]
  • [Cites] J Clin Invest. 2000 Apr;105(7):985-93 [10749577.001]
  • [Cites] J Viral Hepat. 2000 May;7(3):196-202 [10849261.001]
  • [Cites] Semin Liver Dis. 2000;20(2):173-83 [10946422.001]
  • [Cites] N Engl J Med. 2000 Oct 5;343(14):1020-34 [11018170.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1317-23 [11054390.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):2986-91 [11110785.001]
  • [Cites] J Virol. 2001 Jul;75(13):6095-106 [11390611.001]
  • [Cites] J Virol. 2001 Jul;75(13):6209-11 [11390624.001]
  • [Cites] N Engl J Med. 2001 Jul 5;345(1):41-52 [11439948.001]
  • [Cites] J Virol. 2001 Aug;75(15):7059-66 [11435586.001]
  • [Cites] J Immunol. 2003 Mar 15;170(6):3429-39 [12626604.001]
  • [Cites] Hepatology. 2003 Jun;37(6):1343-50 [12774013.001]
  • [Cites] J Neurovirol. 2003 Jun;9(3):291-9 [12775413.001]
  • [Cites] J Med Virol. 2003 Aug;70(4):562-70 [12794718.001]
  • [Cites] Lancet. 2003 Dec 20;362(9401):2095-100 [14697814.001]
  • [Cites] NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46 [14768714.001]
  • [Cites] J Interferon Cytokine Res. 2004 Feb;24(2):107-18 [14980075.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Mar 1;19(5):551-62 [14987324.001]
  • [Cites] Annu Rev Immunol. 2004;22:157-80 [15032577.001]
  • [Cites] Annu Rev Immunol. 2004;22:891-928 [15032599.001]
  • [Cites] J Clin Invest. 2004 Apr;113(8):1158-67 [15085195.001]
  • [Cites] Hepatology. 2004 May;39(5):1220-9 [15122750.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2265-71 [15163776.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1721-31 [15185314.001]
  • [Cites] Hepatology. 2004 Jul;40(1):87-97 [15239090.001]
  • [Cites] J Leukoc Biol. 2004 Sep;76(3):701-8 [15178708.001]
  • [Cites] Hepatology. 2004 Aug;40(2):327-34 [15368437.001]
  • [Cites] J Immunol. 1991 Aug 1;147(3):883-92 [1650387.001]
  • [Cites] J Exp Med. 1992 Aug 1;176(2):587-92 [1380064.001]
  • [Cites] J Immunol. 1992 Sep 15;149(6):2163-71 [1381398.001]
  • [Cites] Hepatology. 1996 Aug;24(2):289-93 [8690394.001]
  • [Cites] Lancet. 1997 Mar 22;349(9055):825-32 [9121257.001]
  • [Cites] J Immunol. 1997 Jun 1;158(11):5536-44 [9164978.001]
  • [Cites] Science. 1998 Oct 2;282(5386):103-7 [9756471.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1485-92 [9819446.001]
  • [Cites] Hepatology. 1999 Sep;30(3):787-93 [10462387.001]
  • [Cites] J Clin Invest. 2001 Nov;108(9):1331-9 [11696578.001]
  • (PMID = 15860662.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI060561; United States / NIAID NIH HHS / AI / U01AI49712; United States / NIAID NIH HHS / AI / R01AI60561; United States / NIAID NIH HHS / AI / AI060561-04; United States / NIAID NIH HHS / AI / R01 AI060561-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / CXCL10 protein, human; 0 / CXCL11 protein, human; 0 / CXCL9 protein, human; 0 / CXCR3 protein, human; 0 / Chemokine CXCL10; 0 / Chemokine CXCL11; 0 / Chemokine CXCL9; 0 / Chemokines, CXC; 0 / Intercellular Signaling Peptides and Proteins; 0 / Receptors, CXCR3; 0 / Receptors, Chemokine
  • [Other-IDs] NLM/ PMC1895193
  •  go-up   go-down


15. Dean J, McCarthy D, Golden-Mason L, O'farrelly C: Trephine biopsies are enriched for activated T/NK cells and cytotoxic T cells. Immunol Lett; 2005 Jun 15;99(1):94-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, T cells, NK cells and T cells expressing NK cell receptor (NKR) molecules were all significantly more likely to express both early (CD69) and late (HLA-DR) markers of activation.
  • [MeSH-minor] Adult. Antigens, CD / immunology. Antigens, CD / metabolism. Biomarkers / analysis. Biomarkers / metabolism. Female. Humans. Immunologic Memory / immunology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Biopsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894117.001).
  • [ISSN] 0165-2478
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers
  •  go-up   go-down


16. Al-Awadhi AM, Alfadhli SM, Al-Khaldi D, Borhama M, Borusly M: Investigation of the distribution of lymphocyte subsets and zinc levels in multitransfused beta-thalassemia major patients. Int J Lab Hematol; 2010 Apr;32(2):191-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • T-cell markers' percentage levels were comparable between patients and controls (P > 0.05), while B cell marker (CD19) was significantly higher in patients (P = 0.007).
  • The high B cell marker may be indicative of stimulation of antibody producing cells as a result of regular blood transfusions.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Male. Reference Standards


17. Martins LR, Lúcio P, Silva MC, Anderes KL, Gameiro P, Silva MG, Barata JT: Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia. Blood; 2010 Oct 14;116(15):2724-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia.
  • Here, we show that CK2 is overexpressed and hyperactivated in chronic lymphocytic leukemia (CLL).
  • CLL cell death upon CK2 inhibition is mediated by inactivation of PKC, a PI3K downstream target, and correlates with increased PTEN activity, indicating that CK2 promotes CLL cell survival at least in part via PI3K-dependent signaling.
  • Overall, our study indicates that CK2 plays a critical role in CLL cell survival, laying the groundwork for the inclusion of CK2 inhibitors into future therapeutic strategies.
  • [MeSH-major] Casein Kinase II / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis / drug effects. Apoptosis / physiology. B-Lymphocytes / drug effects. Case-Control Studies. Cell Survival / drug effects. Cell Survival / physiology. Enzyme Activation. Female. Gene Expression. Humans. In Vitro Techniques. Male. Middle Aged. PTEN Phosphohydrolase / metabolism. Protein Kinase Inhibitors / pharmacology. RNA, Small Interfering / genetics. T-Lymphocytes / drug effects

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20660292.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; EC 2.7.11.1 / Casein Kinase II; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


18. Warnatz K, Salzer U, Rizzi M, Fischer B, Gutenberger S, Böhm J, Kienzler AK, Pan-Hammarström Q, Hammarström L, Rakhmanov M, Schlesier M, Grimbacher B, Peter HH, Eibel H: B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc Natl Acad Sci U S A; 2009 Aug 18;106(33):13945-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans.
  • B-cell survival depends on signals induced by B-cell activating factor (BAFF) binding to its receptor (BAFF-R).
  • In mice, mutations in BAFF or BAFF-R cause B-cell lymphopenia and antibody deficiency.
  • Without BAFF-R, B-cell development is arrested at the stage of transitional B cells and the numbers of all subsequent B-cell stages are severely reduced.
  • They also did not mount a T-independent immune response against pneumococcal cell wall polysaccharides but only one BAFF-R-deficient sibling developed recurrent infections.
  • [MeSH-major] B-Cell Activation Factor Receptor / deficiency. B-Cell Activation Factor Receptor / genetics. Immunologic Deficiency Syndromes / genetics
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Amino Acid Sequence. B-Lymphocytes / metabolism. Cohort Studies. Family Health. Female. Homozygote. Humans. Male. Middle Aged. Molecular Sequence Data


19. Rajasingh J, Raikwar HP, Muthian G, Johnson C, Bright JJ: Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia. Biochem Biophys Res Commun; 2006 Feb 10;340(2):359-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Curcumin induces growth-arrest and apoptosis in association with the inhibition of constitutively active JAK-STAT pathway in T cell leukemia.
  • Adult T cell leukemia is an aggressive and frequently fatal malignancy that expressess constitutively activated growth-signaling pathways in association with deregulated growth and resistance to apoptosis.
  • But the effect and mechanism of action of curcumin on T cell leukemia is not known.
  • To investigate the antitumor activity of curcumin in T cell leukemia, we examined its effect on constitutive phosphorylation of JAK and STAT proteins, proliferation, and apoptosis in HTLV-I-transformed T cell lines.
  • HTLV-I-transformed T cell leukemia lines, MT-2, HuT-102, and SLB-1, express constitutively phosphorylated JAK3, TYK2, STAT3, and STAT5 signaling proteins.
  • In vitro treatment with curcumin induced a dose-dependent decrease in JAK and STAT phosphorylation resulting in the induction of growth-arrest and apoptosis in T cell leukemia.
  • The induction of growth-arrest and apoptosis in association with the blockade of constitutively active JAK-STAT pathway suggests this be a mechanism by which curcumin induces antitumor activity in T cell leukemia.
  • [MeSH-major] Apoptosis / drug effects. Curcumin / pharmacology. Growth Inhibitors / pharmacology. JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors. Leukemia, T-Cell / enzymology. Leukemia, T-Cell / pathology. MAP Kinase Signaling System / drug effects. Protein Kinase Inhibitors / pharmacology
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Transformed. Cell Line, Tumor. Humans. Janus Kinase 3. Phosphorylation / drug effects. Protein-Tyrosine Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / biosynthesis. Protein-Tyrosine Kinases / genetics. STAT3 Transcription Factor / antagonists & inhibitors. STAT3 Transcription Factor / biosynthesis. STAT3 Transcription Factor / genetics. STAT5 Transcription Factor / antagonists & inhibitors. STAT5 Transcription Factor / biosynthesis. STAT5 Transcription Factor / genetics. TYK2 Kinase

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364242.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R21CA106207-01; United States / NINDS NIH HHS / NS / R01 NS42257-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Growth Inhibitors; 0 / JAK3 protein, human; 0 / Protein Kinase Inhibitors; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / STAT5 Transcription Factor; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Janus Kinase 3; EC 2.7.10.2 / TYK2 Kinase; EC 2.7.10.2 / TYK2 protein, human; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; IT942ZTH98 / Curcumin
  •  go-up   go-down


20. Antonelli A, Tardanico R, Balzarini P, Arrighi N, Perucchini L, Zanotelli T, Cozzoli A, Zani D, Cunico SC, Simeone C: Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma. Cancer Genet Cytogenet; 2010 Jun;199(2):128-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic features, clinical significance and prognostic impact of type 1 and type 2 papillary renal cell carcinoma.
  • The purpose of this paper is to evaluate the clinical, pathologic, and cytogenetic features, as well as the disease-free survival in patients with papillary renal cell carcinoma (PRCC) subdivided into types 1 and 2, according to the definition given by Delahunt and Eble.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Chromosome Aberrations. Kidney Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Karyotyping. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate


21. Mondy K, Powderly WG, Claxton SA, Yarasheski KH, Royal M, Stoneman JS, Hoffmann ME, Tebas P: Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr; 2005 Apr 1;38(4):426-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eighty-four percent had an HIV RNA load below 400 copies/mL, with a current median CD4+ T-cell count of 561 cells/mm3 (median nadir CD4 cell count of 167 cells/mm).

  • Genetic Alliance. consumer health - Osteoporosis.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Alendronic acid .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764959.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK049393-08; United States / NIDDK NIH HHS / DK / R01 DK059531; United States / NIDDK NIH HHS / DK / R01 DK049393; United States / NIDDK NIH HHS / DK / R01 DK049393-07; United States / NIAID NIH HHS / AI / AI032783; United States / NIDDK NIH HHS / DK / R01 DK059531-03; United States / NIDDK NIH HHS / DK / R01 DK049393-05; United States / NIDDK NIH HHS / DK / R01 DK059531-02; United States / NIDDK NIH HHS / DK / R01 DK054163; United States / NIDDK NIH HHS / DK / R01 DK059531-01; United States / NIDDK NIH HHS / DK / R01 DK059531-04; United States / NIDDK NIH HHS / DK / R01 DK049393-06; United States / NIAID NIH HHS / AI / AI01612; United States / NIDDK NIH HHS / DK / R01 DK059531-05; United States / NIAID NIH HHS / AI / AI25903
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-16-2 / Vitamin D; SY7Q814VUP / Calcium; X1J18R4W8P / Alendronate
  •  go-up   go-down


22. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD: CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A; 2008 Dec 23;105(51):20410-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
  • Blockade of inhibitory signals mediated by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) has been shown to enhance T cell responses and induce durable clinical responses in patients with metastatic melanoma.
  • One NY-ESO-1 seronegative clinical responder also had a NY-ESO-1 CD4(+) and CD8(+) T cell response, possibly related to prior vaccination with NY-ESO-1.
  • Among five clinical non-responders analyzed, only one had a NY-ESO-1 CD4(+) T cell response and this patient did not have detectable anti-NY-ESO-1 antibody.
  • Overall, NY-ESO-1-specific T cell responses increased in frequency and functionality during anti-CTLA-4 treatment, revealing a polyfunctional response pattern of IFN-gamma, MIP-1beta and TNF-alpha.
  • We therefore suggest that CTLA-4 blockade enhanced NY-ESO-1 antigen-specific B cell and T cell immune responses in patients with durable objective clinical responses and stable disease.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Immunol. 2008 Apr;8(4):247-58 [18323851.001]
  • [Cites] J Exp Med. 1999 Aug 2;190(3):355-66 [10430624.001]
  • [Cites] J Immunol. 2008 Jul 1;181(1):776-84 [18566444.001]
  • [Cites] Cancer Immunol Immunother. 2008 Oct;57(10):1429-37 [18311489.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14987-92 [18818309.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3937-41 [15867394.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] J Immunol. 2005 Dec 1;175(11):7746-54 [16301685.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):764-71 [16467087.001]
  • [Cites] Adv Immunol. 2006;90:297-339 [16730267.001]
  • [Cites] Adv Cancer Res. 2006;95:1-30 [16860654.001]
  • [Cites] Clin Immunol. 2007 Feb;122(2):163-72 [17064965.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2178-84 [17278093.001]
  • [Cites] Cancer Immun. 2007;7:9 [17441676.001]
  • [Cites] J Exp Med. 2007 Jun 11;204(6):1405-16 [17535971.001]
  • [Cites] Oncologist. 2007 Jul;12(7):873-83 [17673618.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6681-8 [17982122.001]
  • [Cites] Eur J Immunol. 2008 Feb;38(2):350-63 [18200635.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10 [18287062.001]
  • [Cites] J Transl Med. 2008;6:22 [18452610.001]
  • [Cites] Immunity. 2000 Apr;12(4):431-40 [10795741.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):295-302 [10899916.001]
  • [Cites] Int J Cancer. 2001 Jun 15;92(6):856-60 [11351307.001]
  • [Cites] J Exp Med. 2001 Aug 20;194(4):481-9 [11514604.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4712-7 [12682289.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702 [15252201.001]
  • [Cites] J Exp Med. 1995 Aug 1;182(2):459-65 [7543139.001]
  • [Cites] Science. 1996 Mar 22;271(5256):1734-6 [8596936.001]
  • [Cites] J Exp Med. 1996 Jun 1;183(6):2541-50 [8676075.001]
  • [Cites] J Exp Med. 1996 Aug 1;184(2):783-8 [8760834.001]
  • [Cites] J Immunol. 1999 May 15;162(10):5813-20 [10229815.001]
  • [CommentIn] J Immunother. 2009 Oct;32(8):884-5 [19752745.001]
  • (PMID = 19074257.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA033049; United States / NCI NIH HHS / CA / P01CA33049; United States / Howard Hughes Medical Institute / /
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CTAG1B protein, human; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Cytokines; 0 / Membrane Proteins; 0 / ipilimumab
  • [Other-IDs] NLM/ PMC2629307
  •  go-up   go-down


23. van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R, Nelson G, Fay JW, Champlin RE, Lazarus HM, Vose JM, Hari PN: Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. Biol Blood Marrow Transplant; 2009 May;15(5):554-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes.
  • We analyzed the outcomes of 283 patients receiving unrelated donor allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma (NHL) facilitated by the Center for International Blood and Marrow Transplant Research/National Marrow Donor Program (CIBMTR/NMDP) between 1991 and 2004.
  • The cumulative incidence of developing grade III-IV acute graft-versus-host disease (aGVHD) at day 100 is 25%.
  • Follicular lymphoma (FL) and peripheral T cell lymphoma had improved survival compared to aggressive B cell lymphomas.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4407-12 [14645431.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1460-8 [15084619.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1923-30 [15191952.001]
  • [Cites] Am J Med. 1980 Aug;69(2):204-17 [6996481.001]
  • [Cites] N Engl J Med. 1993 Mar 4;328(9):593-602 [8429851.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1050-5 [8049425.001]
  • [Cites] Am J Med. 1996 Mar;100(3):299-307 [8629675.001]
  • [Cites] Biol Blood Marrow Transplant. 1997 Aug;3(3):150-6 [9310192.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1832-6 [9716615.001]
  • [Cites] N Engl J Med. 1998 Oct 22;339(17):1177-85 [9780337.001]
  • [Cites] Stat Med. 1999 Jun 30;18(12):1489-500 [10398287.001]
  • [Cites] Ann Oncol. 1999 May;10(5):527-32 [10416001.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3797-803 [15280203.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3865-71 [15304395.001]
  • [Cites] Transfus Apher Sci. 2005 Feb;32(1):45-53 [15737873.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6163-71 [16135483.001]
  • [Cites] Br J Haematol. 2005 Oct;131(2):223-30 [16197454.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56 [16338616.001]
  • [Cites] Blood Rev. 2006 Sep;20(5):235-44 [16513231.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Sep;12(9):954-64 [16920562.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Dec;12(12):1326-34 [17162215.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):85-90 [17336258.001]
  • [Cites] Blood. 2007 May 15;109(10):4586-8 [17234738.001]
  • [Cites] Haematologica. 2007 May;92(5):627-34 [17488686.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Dec;13(12):1499-507 [18022580.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4576-83 [17785583.001]
  • [Cites] Blood. 2008 Jan 1;111(1):446-52 [17916744.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Feb;14(2):236-45 [18215784.001]
  • [Cites] Br J Haematol. 2008 Apr;141(2):235-43 [18318762.001]
  • [Cites] Cancer. 2008 May 1;112(9):1992-2001 [18311781.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2264-71 [18390969.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58 [18541193.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):775-82 [18541196.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5530-6 [18411419.001]
  • [Cites] Bone Marrow Transplant. 2000 Oct;26(8):859-64 [11081385.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3521-9 [12893748.001]
  • (PMID = 19361747.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518-14; United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / U24 CA076518; United States / PHS HHS / / HHSH234200637015C; United States / NCI NIH HHS / CA / U24-CA76518; United States / NCI NIH HHS / CA / CA076518-14; United States / NHLBI NIH HHS / HL / U01 HL069294
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS219378; NLM/ PMC3120935
  •  go-up   go-down


24. Heeregrave EJ, Geels MJ, Brenchley JM, Baan E, Ambrozak DR, van der Sluis RM, Bennemeer R, Douek DC, Goudsmit J, Pollakis G, Koup RA, Paxton WA: Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets. Virology; 2009 Oct 10;393(1):24-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets.
  • Viral compartmentalization between naïve and memory CD4(+) T cell subsets has been described, but only for individuals who were receiving antiretroviral therapy (ART).
  • We present here an extensive analysis of the viral quasispecies residing in the naïve, central and effector memory CD4(+) T cell subsets in a number of therapy naïve individuals and representing an array of HIV-1 subtypes.
  • Our findings emphasize the importance of all CD4(+) T cell subsets to viral evolution.
  • [MeSH-minor] Adult. Cluster Analysis. DNA, Viral / chemistry. DNA, Viral / genetics. Female. Genotype. Humans. Male. Middle Aged. Molecular Sequence Data. Phylogeny. Sequence Analysis, DNA. Young Adult

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • LANL HIV Databases. LANL HIV Databases .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2003 Jul 3;424(6944):99-103 [12808466.001]
  • [Cites] AIDS Res Hum Retroviruses. 2003 Oct;19(10):847-56 [14585216.001]
  • [Cites] J Virol. 2003 Dec;77(23):12430-40 [14610167.001]
  • [Cites] J Virol. 2004 Jan;78(1):524-30 [14671134.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1909-22 [14676302.001]
  • [Cites] J Virol. 2004 Feb;78(3):1160-8 [14722271.001]
  • [Cites] J Virol. 2004 Mar;78(6):2841-52 [14990703.001]
  • [Cites] J Virol. 2004 Aug;78(15):7883-93 [15254161.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):749-59 [15365096.001]
  • [Cites] J Clin Microbiol. 1990 Mar;28(3):495-503 [1691208.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1925-30 [9050881.001]
  • [Cites] J Virol. 1997 Sep;71(9):6348-58 [9261352.001]
  • [Cites] Science. 1998 Apr 17;280(5362):427-31 [9545219.001]
  • [Cites] Clin Exp Immunol. 1999 Mar;115(3):443-50 [10193416.001]
  • [Cites] J Virol. 1999 Aug;73(8):6430-5 [10400736.001]
  • [Cites] J Infect Dis. 1999 Oct;180(4):1106-15 [10479137.001]
  • [Cites] J Exp Med. 2004 Nov 15;200(10):1299-314 [15545355.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1093-7 [15793563.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1148-52 [15793562.001]
  • [Cites] Curr Opin Immunol. 2005 Jun;17(3):326-32 [15886125.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):507-18 [16044000.001]
  • [Cites] AIDS. 2005 Nov 4;19(16):1739-50 [16227781.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):267-75 [16249699.001]
  • [Cites] J Immunol. 2005 Dec 15;175(12):8415-23 [16339584.001]
  • [Cites] Virology. 2006 Feb 5;345(1):209-19 [16246391.001]
  • [Cites] Virology. 2006 Apr 25;348(1):35-46 [16455126.001]
  • [Cites] Retrovirology. 2006;3:52 [16916447.001]
  • [Cites] J Leukoc Biol. 2006 Nov;80(5):1118-26 [17056765.001]
  • [Cites] J Virol. 2007 Jan;81(2):599-612 [17065209.001]
  • [Cites] PLoS Comput Biol. 2007 Feb 16;3(2):e29 [17305421.001]
  • [Cites] J Virol. 2007 Aug;81(15):8165-79 [17507486.001]
  • [Cites] Mol Biol Evol. 2007 Aug;24(8):1596-9 [17488738.001]
  • [Cites] J Exp Med. 2007 Sep 3;204(9):2171-85 [17724130.001]
  • [Cites] Infect Genet Evol. 2008 Mar;8(2):110-20 [18249158.001]
  • [Cites] J Virol. 1999 Dec;73(12):10489-502 [10559367.001]
  • [Cites] Science. 1999 Nov 12;286(5443):1353-7 [10558989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1269-74 [10655520.001]
  • [Cites] J Infect Dis. 2000 Feb;181(2):740-5 [10669367.001]
  • [Cites] J Virol. 2000 Jun;74(11):5347-51 [10799612.001]
  • [Cites] J Infect Dis. 2000 Jul;182(1):112-22 [10882588.001]
  • [Cites] J Virol. 2000 Nov;74(21):10229-35 [11024154.001]
  • [Cites] J Clin Invest. 2000 Oct;106(8):1039-52 [11032864.001]
  • [Cites] J Virol. 2000 Dec;74(23):11001-7 [11069995.001]
  • [Cites] Nat Immunol. 2000 Oct;1(4):285-9 [11017098.001]
  • [Cites] J Biol Chem. 2001 Apr 20;276(16):13433-41 [11278567.001]
  • [Cites] Immunity. 2001 Oct;15(4):671-82 [11672548.001]
  • [Cites] Clin Exp Immunol. 2001 Oct;126(1):69-75 [11678901.001]
  • [Cites] Nature. 2002 May 2;417(6884):95-8 [11986671.001]
  • [Cites] AIDS. 2002 Jun 14;16(9):1245-9 [12045489.001]
  • [Cites] J Virol. 2002 Sep;76(18):9465-73 [12186928.001]
  • [Cites] AIDS. 2002 Nov 22;16(17):2337-40 [12441808.001]
  • [Cites] Annu Rev Immunol. 2003;21:265-304 [12524385.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2711-20 [12433688.001]
  • [Cites] J Virol. 2008 Sep;82(18):9154-63 [18596085.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):126-36 [19131897.001]
  • [Cites] J Virol. 1992 May;66(5):3183-7 [1560543.001]
  • [Cites] J Infect Dis. 1996 Feb;173(2):349-54 [8568295.001]
  • [Cites] Science. 1996 Mar 15;271(5255):1582-6 [8599114.001]
  • [Cites] Science. 1996 Apr 26;272(5261):537-42 [8614801.001]
  • [Cites] Cell. 1996 Aug 9;86(3):367-77 [8756719.001]
  • [Cites] Nat Med. 1997 Feb;3(2):205-11 [9018240.001]
  • (PMID = 19698967.001).
  • [ISSN] 1096-0341
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ GQ389219/ GQ389220/ GQ389221/ GQ389222/ GQ389223/ GQ389224/ GQ389225/ GQ389226/ GQ389227/ GQ389228/ GQ389229/ GQ389230/ GQ389231
  • [Grant] United States / Intramural NIH HHS / / Z01 AI005014-06; United States / Intramural NIH HHS / / Z99 AI999999
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ NIHMS134349; NLM/ PMC2753733
  •  go-up   go-down


25. Trubia M, Albano F, Cavazzini F, Cambrin GR, Quarta G, Fabbiano F, Ciambelli F, Magro D, Hernandezo JM, Mancini M, Diverio D, Pelicci PG, Coco FL, Mecucci C, Specchia G, Rocchi M, Liso V, Castoldi G, Cuneo A: Characterization of a recurrent translocation t(2;3)(p15-22;q26) occurring in acute myeloid leukaemia. Leukemia; 2006 Jan;20(1):48-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of a recurrent translocation t(2;3)(p15-22;q26) occurring in acute myeloid leukaemia.
  • Six patients with de novo acute myeloid leukemia (AML) and a t(2;3)(p15-21;q26-27) were identified among approximately 1000 cases enrolled in the GIMEMA trial.
  • The patients showed dysplasia of at least two myeloid cell lineages in all cases; they had a low-to-normal platelet count and displayed an immature CD34+ CD117+ immunophenotype.
  • We arrived at the following conclusions: (a) the t(2;3) is a recurrent translocation having an approximate 0.5% incidence in adult AML;.
  • [MeSH-major] Chromosomes, Human, Pair 2 / genetics. Chromosomes, Human, Pair 3 / genetics. Leukemia, Myeloid / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adult. Cytogenetic Analysis / methods. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged. Polymerase Chain Reaction. Predictive Value of Tests. Prognosis. Trisomy

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619048.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


26. Kobayashi M, Hattori M, Miyamoto T, Kakinuma H, Watanabe J, Iwabuchi K, Nishimura Y, Jobo T, Kuramoto H: Basement membrane-like substance in cytologic diagnosis in clear cell adenocarcinoma of the minor salivary gland of the palate. A case report. Acta Cytol; 2007 Nov-Dec;51(6):916-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basement membrane-like substance in cytologic diagnosis in clear cell adenocarcinoma of the minor salivary gland of the palate. A case report.
  • BACKGROUND: Clear cell adenocarcinoma (CCA) of the minor salivary gland accounts for < 1% of all tumors of the salivary gland.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Basement Membrane / pathology. Palatal Neoplasms / pathology. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Cytodiagnosis / methods. Disease-Free Survival. Female. Humans. Laminin / metabolism. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077986.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Laminin
  •  go-up   go-down


27. Hom J, Yu T, Yoon Y, Porter G, Sheu SS: Regulation of mitochondrial fission by intracellular Ca2+ in rat ventricular myocytes. Biochim Biophys Acta; 2010 Jun-Jul;1797(6-7):913-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Calcium (Ca2+) is one signal that has been shown to both regulate mitochondrial fission in various cell types and stimulate mitochondrial enzymes involved in ATP generation.
  • However, although Ca2+ plays an important role in adult cardiac muscle cells for excitation-metabolism coupling, little is known about whether Ca2+ can regulate their mitochondrial morphology.
  • We found that neonatal and adult cardiomyocyte mitochondria undergo rapid and transient fragmentation upon a thapsigargin (TG)- or KCl-induced cytosolic Ca2+ increase.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • [Cites] Trends Pharmacol Sci. 1998 Apr;19(4):131-5 [9612087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2653-8 [16477035.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):351-8 [9786947.001]
  • [Cites] J Biol Chem. 1998 Nov 27;273(48):32158-66 [9822693.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Jun;288(6):C1440-50 [15647387.001]
  • [Cites] J Biol Chem. 2005 Jul 15;280(28):26185-92 [15899901.001]
  • [Cites] Mol Biol Cell. 1999 Dec;10(12):4403-17 [10588666.001]
  • [Cites] Mol Cell. 1999 Nov;4(5):815-26 [10619028.001]
  • [Cites] Nat Genet. 2000 Oct;26(2):207-10 [11017079.001]
  • [Cites] Nat Genet. 2000 Oct;26(2):211-5 [11017080.001]
  • [Cites] Mol Biol Cell. 2001 Aug;12(8):2245-56 [11514614.001]
  • [Cites] Mol Biol Cell. 2001 Sep;12(9):2894-905 [11553726.001]
  • [Cites] J Bioenerg Biomembr. 2000 Feb;32(1):97-104 [11768767.001]
  • [Cites] Curr Atheroscler Rep. 2002 Mar;4(2):149-55 [11822979.001]
  • [Cites] J Cell Sci. 2002 Apr 15;115(Pt 8):1663-74 [11950885.001]
  • [Cites] Toxicol Sci. 2002 Dec;70(2):261-8 [12441371.001]
  • [Cites] J Cell Biol. 2003 Jan 20;160(2):189-200 [12527753.001]
  • [Cites] J Cell Biol. 2003 Mar 31;160(7):1115-27 [12668660.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):17190-7 [12598526.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2763-74 [12759376.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(15):5409-20 [12861026.001]
  • [Cites] Curr Biol. 2004 Feb 17;14(4):340-5 [14972687.001]
  • [Cites] Nat Genet. 2004 May;36(5):449-51 [15064763.001]
  • [Cites] Neurol Sci. 2004 Jun;25(2):72-82 [15221625.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1019:70-7 [15246997.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Oct;287(4):C817-33 [15355853.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Circulation. 1975 Jan;51(1):39-67 [122789.001]
  • [Cites] Histopathology. 1978 May;2(3):215-23 [669594.001]
  • [Cites] Circ Res. 1984 Dec;55(6):830-4 [6499138.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Apr;87(7):2466-70 [2138778.001]
  • [Cites] Circulation. 1991 Feb;83(2):504-14 [1991369.001]
  • [Cites] Exp Cell Res. 1994 May;212(1):84-92 [8174645.001]
  • [Cites] Cancer Lett. 1994 May 16;79(2):147-55 [8019972.001]
  • [Cites] Cardioscience. 1994 Jun;5(2):127-38 [7919049.001]
  • [Cites] J Cell Biol. 1996 May;133(4):761-75 [8666662.001]
  • [Cites] Circ Res. 1996 Jul;79(1):86-93 [8925573.001]
  • [Cites] J Cell Biol. 1998 Feb 23;140(4):779-93 [9472031.001]
  • [Cites] J Cell Sci. 1998 May;111 ( Pt 10):1341-9 [9570752.001]
  • [Cites] J Cell Sci. 2005 Sep 15;118(Pt 18):4141-51 [16118244.001]
  • [Cites] J Cell Biol. 2005 Sep 26;170(7):1021-7 [16186251.001]
  • [Cites] EMBO Rep. 2006 Oct;7(10):1019-22 [16936636.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):11521-9 [17301055.001]
  • [Cites] N Engl J Med. 2007 Apr 26;356(17):1736-41 [17460227.001]
  • [Cites] J Cell Physiol. 2007 Aug;212(2):498-508 [17443673.001]
  • [Cites] J Biol Chem. 2007 Jul 27;282(30):21583-7 [17553808.001]
  • [Cites] EMBO Rep. 2007 Oct;8(10):939-44 [17721437.001]
  • [Cites] Neurosci Res. 2008 Jan;60(1):114-9 [18045716.001]
  • [Cites] Cardiovasc Res. 2008 Jul 15;79(2):341-51 [18440987.001]
  • [Cites] J Neurochem. 2008 Jul;106(1):372-83 [18419770.001]
  • [Cites] Cell. 2008 Jul 25;134(2):279-90 [18662543.001]
  • [Cites] J Mol Cell Cardiol. 2009 Jun;46(6):811-20 [19281816.001]
  • [Cites] Mol Cell Biochem. 1998 Sep;186(1-2):159-68 [9774197.001]
  • (PMID = 20347716.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL033333-21; United States / NIDDK NIH HHS / DK / DK 61991; United States / NIDDK NIH HHS / DK / R21 DK073858-02; United States / NHLBI NIH HHS / HL / HL 33333; United States / NHLBI NIH HHS / HL / R01 HL033333-21; United States / NHLBI NIH HHS / HL / R01 HL033333; United States / NIDDK NIH HHS / DK / R01 DK061991; United States / NIDDK NIH HHS / DK / R01 DK061991-06A2; United States / NHLBI NIH HHS / HL / R01 HL093671-01A1; United States / NIDDK NIH HHS / DK / DK 73858; United States / NIDDK NIH HHS / DK / R01 DK078618; United States / NIDDK NIH HHS / DK / R21 DK073858; United States / NIDDK NIH HHS / DK / DK073858-02; United States / NHLBI NIH HHS / HL / R01 HL093671; United States / NIDDK NIH HHS / DK / DK061991-06A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Microtubule-Associated Proteins; 0 / Mitochondrial Proteins; 0 / Reactive Oxygen Species; 11062-77-4 / Superoxides; 67526-95-8 / Thapsigargin; EC 3.6.1.- / GTP Phosphohydrolases; EC 3.6.5.5 / Drp1 protein, rat; EC 3.6.5.5 / Dynamins; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS199418; NLM/ PMC2891135
  •  go-up   go-down


28. Rahma OE, Ashtar E, Ibrahim R, Toubaji A, Gause B, Herrin VE, Linehan WM, Steinberg SM, Grollman F, Grimes G, Bernstein SA, Berzofsky JA, Khleif SN: A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J Transl Med; 2010;8:8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.
  • BACKGROUND: Due to the lack of specific tumor antigens, the majority of tested cancer vaccines for renal cell carcinoma (RCC) are based on tumor cell lysate.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / immunology. Carcinoma, Renal Cell / prevention & control. Peptides. Von Hippel-Lindau Tumor Suppressor Protein
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Pilot Projects. T-Lymphocytes, Regulatory / immunology. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Sep 1;87(5):650-3 [10925357.001]
  • [Cites] Int J Oncol. 2009 Sep;35(3):569-81 [19639177.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7925-33 [11691814.001]
  • [Cites] J Urol. 2002 Jan;167(1):57-60 [11743275.001]
  • [Cites] Eur J Immunol. 2001 Nov;31(11):3261-70 [11745343.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3127-32 [12915604.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):4016-26 [14581425.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Expert Opin Biol Ther. 2004 Nov;4(11):1791-801 [15500407.001]
  • [Cites] J Urol. 1977 Oct;118(4):538-42 [916044.001]
  • [Cites] J Urol. 1988 Sep;140(3):596-7 [3411682.001]
  • [Cites] Res Immunol. 1991 Jun-Aug;142(5-6):425-9 [1754715.001]
  • [Cites] J Immunother (1991). 1991 Oct;10(5):313-25 [1790139.001]
  • [Cites] Reg Immunol. 1992 Jul-Aug;4(4):225-35 [1476875.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2852-5 [8187067.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):685-90 [7834641.001]
  • [Cites] JAMA. 1995 Feb 15;273(7):564-70 [7837390.001]
  • [Cites] World J Urol. 1995;13(3):171-3 [7550390.001]
  • [Cites] Int J Cancer. 1996 Oct 9;68(2):177-82 [8900424.001]
  • [Cites] Semin Immunol. 1996 Oct;8(5):289-93 [8956457.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):987-9 [9307203.001]
  • [Cites] Cell Immunol. 1997 Dec 15;182(2):137-51 [9514698.001]
  • [Cites] N Engl J Med. 1998 Apr 30;338(18):1305-6 [9562587.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4090-5 [9751617.001]
  • [Cites] J Urol. 1999 Mar;161(3):777-82 [10022683.001]
  • [Cites] J Immunother. 1999 Mar;22(2):155-65 [10093040.001]
  • [Cites] JAMA. 1999 May 5;281(17):1628-31 [10235157.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Dec;31(13):2095-9 [15628750.001]
  • [Cites] Curr Med Chem. 2005;12(13):1481-94 [15974981.001]
  • [Cites] Cytotherapy. 2005;7(1):23-35 [16040381.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5099-107 [15983396.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4 [16985252.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] Discov Med. 2006 Oct;6(35):175-81 [17234138.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):671s-679s [17255292.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 4;99(7):569-70; author reply 570-1 [17406001.001]
  • [Cites] Am J Health Syst Pharm. 2008 Jan 15;65(2):123-31 [18192256.001]
  • [Cites] World J Urol. 2008 Apr;26(2):147-54 [18335222.001]
  • [Cites] Cancer Immunol Immunother. 2008 Sep;57(9):1413-20 [18297281.001]
  • [Cites] Hum Vaccin. 2008 Jul-Aug;4(4):262-70 [18398303.001]
  • [Cites] Expert Opin Biol Ther. 2008 Sep;8(9):1365-79 [18694355.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):966-70 [11583750.001]
  • (PMID = 20109232.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Peptides; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ PMC2843651
  •  go-up   go-down


29. Caciotti A, Donati MA, Boneh A, d'Azzo A, Federico A, Parini R, Antuzzi D, Bardelli T, Nosi D, Kimonis V, Zammarchi E, Morrone A: Role of beta-galactosidase and elastin binding protein in lysosomal and nonlysosomal complexes of patients with GM1-gangliosidosis. Hum Mutat; 2005 Mar;25(3):285-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GLB1 forms a complex with protective protein cathepsin A (PPCA), alpha neuraminidase (NEU1), and galactosamine 6-sulphate sulfatase (GALNS) inside lysosomes, while EBP binds to PPCA and NEU1 on the cell surface.
  • [MeSH-major] Gangliosidosis, GM1 / genetics. Receptors, Cell Surface / physiology. beta-Galactosidase / physiology
  • [MeSH-minor] Adult. Alternative Splicing. Amino Acid Sequence. Amino Acid Substitution. Animals. COS Cells. Cathepsin A / chemistry. Cells, Cultured / metabolism. Cercopithecus aethiops. Elastic Tissue / ultrastructure. Female. Fibroblasts / metabolism. Humans. Infant. Infant, Newborn. Lysosomes / enzymology. Male. Molecular Sequence Data. Multiprotein Complexes. Mutation, Missense. Phenotype. Protein Binding. Protein Folding. Protein Interaction Mapping. Sequence Alignment. Sequence Homology, Amino Acid. Species Specificity. Transfection

  • Genetic Alliance. consumer health - GM1 gangliosidosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15714521.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multiprotein Complexes; 0 / Receptors, Cell Surface; 0 / elastin-binding proteins; EC 3.2.1.23 / GLB1 protein, human; EC 3.2.1.23 / beta-Galactosidase; EC 3.4.16.5 / Cathepsin A
  •  go-up   go-down


30. Pessoa SD, Miyamoto M, Ono E, Gouvêa AF, de Moraes-Pinto MI, Succi RC: Persistence of vaccine immunity against hepatitis B virus and response to revaccination in vertically HIV-infected adolescents on HAART. Vaccine; 2010 Feb 10;28(6):1606-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adolescents of HIV group with anti-HBs>or=1 0 mIU/mL presented a higher CD4+ T cell percentage, higher naïve and central memory CD8+ T cell percentages and lower immune activation markers.
  • Those adolescents who did not respond to revaccination presented a lower CD4+ T cell percentage, higher immune activation markers and more frequently detectable HIV viral load.
  • We concluded that lower immune activation, higher CD4+ T cell percentage and better control of HIV replication may be associated with hepatitis B vaccine response.
  • [MeSH-minor] Adolescent. CD4-CD8 Ratio. CD8-Positive T-Lymphocytes / immunology. Child. HIV / isolation & purification. Hepatitis B Antibodies / blood. Humans. Time Factors. Viral Load. Young Adult


31. Gollnick H, Barona CG, Frank RG, Ruzicka T, Megahed M, Maus J, Munzel U: Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol; 2008 Nov-Dec;18(6):677-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe.
  • Imiquimod 5% cream is an immune response modifier approved for the treatment of superficial basal cell carcinoma (sBCC) once daily, 5 x per week for 6 weeks.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Neoplasm Recurrence, Local. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955210.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


32. McTiernan CF, Mathier MA, Zhu X, Xiao X, Klein E, Swan CH, Mehdi H, Gibson G, Trichel AM, Glorioso JC, Feldman AM, McCurry KR, London B: Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts. Gene Ther; 2007 Dec;14(23):1613-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adult baboons received direct cardiac injections of AAV-TNFRII-Fc ( approximately 5 x 10(12) viral/genomes/baboon) or an equivalent dose of AAV-2 empty capsids, and were analyzed after 5 or 12 weeks.
  • Viral genomes were restricted to the myocardium, and routine analyses (blood cell counts, clinical chemistries) remained unremarkable.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851548.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / U01HL66949
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Fc Fragments; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


33. Wang Y, Cela E, Gagnon S, Sweezey NB: Estrogen aggravates inflammation in Pseudomonas aeruginosa pneumonia in cystic fibrosis mice. Respir Res; 2010;11:166
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Exogenous E2 caused adult male CF mice with pneumonia due to a mucoid CF clinical isolate, the P. aeruginosa strain PA508 (PA508), to develop more severe manifestations of inflammation in both lung tissue and in bronchial alveolar lavage (BAL) fluid, with increased total white blood cell counts and differential and absolute cell counts of polymorphonuclear leukocytes (neutrophils).
  • CONCLUSIONS: Our data show that E2 increases the severity of PA508 pneumonia in adult CF male mice, and suggest two potential mechanisms: enhancement of Th17-regulated inflammation and suppression of innate antibacterial defences.

  • MedlinePlus Health Information. consumer health - Cystic Fibrosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Respir Cell Mol Biol. 2005 Aug;33(2):138-44 [15879161.001]
  • [Cites] Lab Anim. 2005 Jul;39(3):336-52 [16004694.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1123-32 [16200070.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Feb 1;173(3):288-96 [16272448.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Mar 1;173(5):475-82 [16126935.001]
  • [Cites] Health Qual Life Outcomes. 2006;4:5 [16433917.001]
  • [Cites] J Allergy Clin Immunol. 2006 May;117(5):1163-9 [16675347.001]
  • [Cites] J Allergy Clin Immunol. 2006 Jul;118(1):143-51 [16815150.001]
  • [Cites] Am J Respir Cell Mol Biol. 2006 Sep;35(3):327-36 [16614352.001]
  • [Cites] Thorax. 2006 Nov;61(11):969-74 [16844728.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2007 Feb;292(2):L519-28 [17071720.001]
  • [Cites] Clin Chest Med. 2007 Jun;28(2):331-46 [17467552.001]
  • [Cites] Pediatr Pulmonol. 2007 Jun;42(6):513-8 [17469151.001]
  • [Cites] Pediatr Pulmonol. 2007 Jun;42(6):519-24 [17469152.001]
  • [Cites] Inflamm Res. 2007 Jun;56(6):221-7 [17607545.001]
  • [Cites] J Pediatr. 2007 Aug;151(2):134-9, 139.e1 [17643762.001]
  • [Cites] Endocr Rev. 2007 Aug;28(5):521-74 [17640948.001]
  • [Cites] Pediatr Pulmonol. 2008 May;43(5):463-71 [18361452.001]
  • [Cites] Am J Respir Cell Mol Biol. 2008 May;38(5):499-500 [18417757.001]
  • [Cites] J Clin Invest. 2008 Dec;118(12):3841-4 [19033654.001]
  • [Cites] J Clin Invest. 2008 Dec;118(12):4025-35 [19033671.001]
  • [Cites] J Leukoc Biol. 2010 Mar;87(3):501-8 [20007247.001]
  • [Cites] Immunology. 2000 Jul;100(3):384-90 [10929062.001]
  • [Cites] Semin Immunopathol. 2010 Mar;32(1):3-16 [20107806.001]
  • [Cites] Cell Mol Life Sci. 2010 May;67(10):1661-74 [20140748.001]
  • [Cites] Respir Res. 2010;11:78 [20565710.001]
  • [Cites] Am J Respir Crit Care Med. 2010 Jul 1;182(1):62-72 [20378727.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):762-4 [11048725.001]
  • [Cites] J Gend Specif Med. 1999 Mar-Apr;2(2):47-51 [11252861.001]
  • [Cites] Infect Immun. 2001 Aug;69(8):5138-50 [11447196.001]
  • [Cites] Pediatr Pulmonol. 2001 Nov;32(5):356-66 [11596160.001]
  • [Cites] Respir Res. 2000;1(3):141-50 [11667978.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Apr 1;165(7):904-10 [11934712.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Jun;26(6):748-53 [12034575.001]
  • [Cites] Nature. 2002 May 30;417(6888):552-5 [12037568.001]
  • [Cites] Immunology. 2002 Nov;107(3):297-305 [12423305.001]
  • [Cites] Adv Drug Deliv Rev. 2002 Dec 5;54(11):1359-71 [12458149.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Jun;30(6):777-83 [14656745.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Oct;31(4):377-81 [15381503.001]
  • [Cites] Pediatr Pulmonol. 1992 Mar;12(3):158-61 [1641272.001]
  • [Cites] Science. 1992 Aug 21;257(5073):1083-8 [1380723.001]
  • [Cites] Antimicrob Agents Chemother. 1994 May;38(5):1090-5 [8067743.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Apr;151(4):1075-82 [7697234.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Apr;151(4):939-41 [7697269.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2111-8 [8520783.001]
  • [Cites] Am J Epidemiol. 1996 May 15;143(10):1007-17 [8629607.001]
  • [Cites] Am J Epidemiol. 1997 May 1;145(9):794-803 [9143209.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 22;876:426-9 [10415638.001]
  • [Cites] Am J Physiol. 1999 Jul;277(1 Pt 1):C35-42 [10409106.001]
  • [Cites] Eur Respir J. 1999 Aug;14(2):339-46 [10515411.001]
  • [Cites] JAMA. 2005 Feb 2;293(5):581-8 [15687313.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Apr;288(4):C881-90 [15761213.001]
  • [Cites] Infect Immun. 2005 Jun;73(6):3693-701 [15908399.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):404-12 [15972674.001]
  • [Cites] J Cyst Fibros. 2005 Aug;4 Suppl 2:15-23 [15967736.001]
  • (PMID = 21118573.001).
  • [ISSN] 1465-993X
  • [Journal-full-title] Respiratory research
  • [ISO-abbreviation] Respir. Res.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK027651
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogens
  • [Other-IDs] NLM/ PMC3006363
  •  go-up   go-down


34. Muretto P: The relationship of Langerhans cells to melanocytes and Schwann cells in mature cystic teratomas of the ovary. Int J Surg Pathol; 2007 Jul;15(3):266-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD1-positive LCs sometimes appeared to cross the basal membrane and penetrate the subepidermal tissue (related to their known migratory ability), and they were associated there with T-cell line lymphocytes (CD3 positive).
  • Finally, we propose that LCs may be part of a cytoimmunologic system related to the T-cell compartment, with a stem cell derived from the neural crest.
  • [MeSH-minor] Adult. Antigens, CD1 / genetics. Antigens, CD1 / metabolism. Antigens, CD3 / genetics. Antigens, CD3 / metabolism. Cell Differentiation. Cell Transformation, Neoplastic / pathology. Female. Gene Expression Regulation, Neoplastic. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652534.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD1; 0 / Antigens, CD3
  •  go-up   go-down


35. Murata K, Yamada Y: The state of the art in the pathogenesis of ATL and new potential targets associated with HTLV-1 and ATL. Int Rev Immunol; 2007 Sep-Dec;26(5-6):249-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Almost 30 years have passed since adult T-cell leukemia (ATL) was identified as a new disease entity in Japan.
  • During this period, its causative agent, human T-cell leukemia virus (HTLV-1), was discovered, and a crucial role of the viral product Tax in ATL leukemogenesis was demonstrated.
  • Recently, another HTLV-1 product, HBZ, which is encoded on the negative strand, was found, and it has now become a subject of intensive research because of its possible activity in cell proliferation.
  • [MeSH-major] Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18027200.001).
  • [ISSN] 0883-0185
  • [Journal-full-title] International reviews of immunology
  • [ISO-abbreviation] Int. Rev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic-Leucine Zipper Transcription Factors; 0 / CCR4 protein, human; 0 / Gene Products, tax; 0 / HBZ protein, human T-cell leukemia virus type I; 0 / NF-kappa B; 0 / Receptors, CCR4; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Viral Proteins
  • [Number-of-references] 90
  •  go-up   go-down


36. Manchanda PK, Singh R, Mittal RD: Cytokine (IL-10 -1082 and -819) and chemokine receptor (CCR2 and CCR5) gene polymorphism in North Indian patients with end-stage renal disease. DNA Cell Biol; 2009 Apr;28(4):177-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. India. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19196047.001).
  • [ISSN] 1557-7430
  • [Journal-full-title] DNA and cell biology
  • [ISO-abbreviation] DNA Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCR2 protein, human; 0 / IL10 protein, human; 0 / Receptors, CCR2; 0 / Receptors, CCR5; 130068-27-8 / Interleukin-10
  •  go-up   go-down


37. Yang SH, Mechanic LE, Yang P, Landi MT, Bowman ED, Wampfler J, Meerzaman D, Hong KM, Mann F, Dracheva T, Fukuoka J, Travis W, Caporaso NE, Harris CC, Jen J: Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res; 2005 Mar 15;11(6):2106-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer.
  • We evaluated somatic genetic alterations in the kinase domain of the EGFR gene in the tumors of 219 non-small cell lung cancer patients of primarily Caucasian and African American origins.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation / genetics. Protein-Tyrosine Kinases / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. African Americans. Aged. Aged, 80 and over. European Continental Ancestry Group. Female. Humans. Male. Middle Aged. Protein Structure, Tertiary. Smoking

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2005 Nov 1;11(21):7960-1
  • (PMID = 15788655.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 80127; United States / NCI NIH HHS / CA / CA 84354
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


38. Karczewski J, Karczewski M, Wiktorowicz K: Possible defect of T suppressor cell subpopulation in patients with kidney acute rejection. Transplant Proc; 2010 Dec;42(10):4538-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible defect of T suppressor cell subpopulation in patients with kidney acute rejection.
  • During the 6-month period following transplantation an acute rejection episode (ARE) was diagnosed in 11 patients based on biopsy results using the Banff criteria.
  • Cytometric analysis did not show significant differences between the groups in pretransplant levels of peripheral CD8(+)CD28(-)Foxp3(+) Ts cells (P > .05); however, the posttransplantation analysis showed a higher mean level of Ts cells in nonrejection (NONARE) versus acute rejection (ARE) patients (P < .0001).
  • Interestingly, we observed similar results with respect to peripheral CD4(+)CD25(+)Foxp3(+) T regulatory cells in ARE patients, suggesting impairment of immunoregulatory mechanisms (especially within the inducible Foxp3 system) in this group, leading to acute renal allograft rejection episodes.
  • [MeSH-minor] Adult. Antigens, CD / immunology. Female. Flow Cytometry. Humans. Male. Middle Aged. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21168732.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


39. Marincsák R, Tóth BI, Czifra G, Márton I, Rédl P, Tar I, Tóth L, Kovács L, Bíró T: Increased expression of TRPV1 in squamous cell carcinoma of the human tongue. Oral Dis; 2009 Jul;15(5):328-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of TRPV1 in squamous cell carcinoma of the human tongue.
  • OBJECTIVES: Recent reports have unambiguously identified the presence and the growth-modulatory role of transient receptor potential vanilloid-1 (TRPV1), a central integrator of pain sensation, on numerous non-neuronal cell types and, of great importance, in certain malignancies.
  • In this study, we have investigated the molecular expression of TRPV1 in the human tongue and its high-incidence malignant (squamous cell carcinoma, SCC) and premalignant (leukoplakia) conditions.
  • Finally, the molecular expression of TRPV1 was also identified in an SCC-derived cell line and was shown to be increased in parallel with the accelerated growth of the cells.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. TRPV Cation Channels / analysis. Tongue Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Blotting, Western. Cell Line, Tumor. Epithelial Cells / pathology. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Leukoplakia, Oral / pathology. Male. Middle Aged. Polymerase Chain Reaction / methods. Tongue / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19320840.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TRPV Cation Channels; 0 / TRPV1 protein, human
  •  go-up   go-down


40. Matsubar Y, Hori T, Morita R, Sakaguchi S, Uchiyama T: Delineation of immunoregulatory properties of adult T-cell leukemia cells. Int J Hematol; 2006 Jul;84(1):63-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delineation of immunoregulatory properties of adult T-cell leukemia cells.
  • We characterized leukemic cells from 20 adult T-cell leukemia (ATL) cases and 7 ATL-derived cell lines in terms of Foxp3 messenger RNA (mRNA) expression, cytokine production, cell surface markers associated with regulatory T-cells (Treg), and in vitro immunoregulatory activity and compared the results with those of cells from 3 T-cell-type chronic lymphocytic leukemia (T-CLL) patients and normal CD4+ T-cells.
  • Real-time polymerase chain reaction analysis showed that cells from 10 ATL cases, 1 T-CLL case, and 1 ATL cell line had higher Foxp3 mRNA levels than CD4+ T-cells.
  • [MeSH-major] Gene Expression Regulation, Leukemic / immunology. Immune Tolerance. Leukemia-Lymphoma, Adult T-Cell / immunology
  • [MeSH-minor] Aged. Cell Line, Tumor. Coculture Techniques. Female. Humans. Male. Middle Aged. T-Lymphocytes, Regulatory / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Immunol. 1999 May;19(3):186-93 [10404404.001]
  • [Cites] Blood. 2016 Dec 15;128(24):2745 [27979862.001]
  • [Cites] J Exp Med. 1985 Dec 1;162(6):2169-74 [2866223.001]
  • [Cites] Cancer Genet Cytogenet. 1981 Apr;3(3):251-9 [6974589.001]
  • (PMID = 16867905.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


41. Minamimoto R, Nakaigawa N, Tateishi U, Suzuki A, Shizukuishi K, Kishida T, Miura T, Makiyama K, Yao M, Kubota Y, Inoue T: Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT. Clin Nucl Med; 2010 Dec;35(12):918-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT.
  • PURPOSE: Multikinase inhibitor (MKI) is a promising drug for treatment of metastatic renal cell carcinoma (mRCC).
  • [MeSH-major] Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / diagnosis. Kidney Neoplasms / drug therapy. Positron-Emission Tomography / methods. Protein Kinase Inhibitors / therapeutic use. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Contrast Media. Disease-Free Survival. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21206220.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Protein Kinase Inhibitors; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


42. Keller M, Lu Y, Lalonde RG, Klein MB: Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare. AIDS; 2009 Mar 27;23(6):731-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of HIV-1 viral subtype on CD4+ T-cell decline and clinical outcomes in antiretroviral naive patients receiving universal healthcare.
  • [MeSH-minor] Adolescent. Adult. Africa South of the Sahara / ethnology. African Continental Ancestry Group / statistics & numerical data. CD4 Lymphocyte Count. CD4-Positive T-Lymphocytes / immunology. Confounding Factors (Epidemiology). Disease Progression. Female. Haiti / ethnology. Humans. Male. Middle Aged. Prognosis. Quebec / epidemiology. Young Adult


43. Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Oyama T, Mori M, Endo K: Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nucl Med Biol; 2010 Nov;37(8):911-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung cancer.
  • OBJECTIVE: L-Type amino acid transporter 1 (LAT1) has associated with tumor growth and poor outcome of patients with non-small cell lung cancer (NSCLC).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / metabolism. Gene Expression Regulation, Neoplastic. Large Neutral Amino Acid-Transporter 1 / metabolism. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Methyltyrosines / metabolism
  • [MeSH-minor] Adult. Aged. Biological Transport. Female. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21055621.001).
  • [ISSN] 1872-9614
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3-fluoro-alpha-methyltyrosine; 0 / Large Neutral Amino Acid-Transporter 1; 0 / Methyltyrosines
  •  go-up   go-down


44. Wahlkvist H, Masjedi K, Gruvberger B, Zuber B, Karlberg AT, Bruze M, Ahlborg N: The lipophilic hapten parthenolide induces interferon-gamma and interleukin-13 production by peripheral blood-derived CD8+ T cells from contact allergic subjects in vitro. Br J Dermatol; 2008 Jan;158(1):70-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Peripheral blood mononuclear cells (PBMC) from persons with contact allergy to nickel react in vitro predominantly with nickel-induced CD4+ T cell-mediated production of both T-cell type 1 and 2 cytokines.
  • PBMC from the subjects were analysed for in vitro reactivity with parthenolide by an enzyme-linked immunospot (ELISpot) assay, measuring cytokine production at the single-cell level.
  • The responses manifested by T-cell type 1 (IFN-gamma and IL-2) and type 2 (IL-4, IL-5 and IL-13) cytokines were positively correlated between cytokines.
  • In contrast to the CD4+ T cell-mediated peripheral reactivity induced by nickel, cell depletion experiments identified the parthenolide-reactive IFN-gamma- and IL-13-producing cells as CD8+ T cells.
  • CONCLUSIONS: The finding that the PBMC reactivity to parthenolide in humans involves a CD8+ T cell-mediated type 1 and 2 cytokine response warrants further studies on the relationship between the chemical nature of a hapten and the resulting immune response.
  • [MeSH-minor] Adult. Cells, Cultured. Dose-Response Relationship, Immunologic. Enzyme-Linked Immunosorbent Assay / methods. Female. Haptens / immunology. Humans. Immunophenotyping. Lymphocyte Activation / immunology. Male. Middle Aged. Patch Tests

  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986299.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Haptens; 0 / Interleukin-13; 0 / Sesquiterpenes; 2RDB26I5ZB / parthenolide; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


45. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA: Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol; 2005 May;173(5):1496-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma.
  • PURPOSE: Approximately 30% of renal cell carcinomas (RCCs) present as metastatic disease.
  • MATERIALS AND METHODS: A custom tissue array was constructed using clear cell RCC from 150 patients with metastatic RCC who underwent nephrectomy prior to immunotherapy.
  • The tissue array was stained for 8 molecular markers, namely Ki67, p53, gelsolin, carbonic anhydrase (CA)9, CA12, PTEN (phosphatase and tensin homologue deleted on chromosome 10), epithelial cell adhesion molecule and vimentin.
  • CONCLUSIONS: In patients with clear cell RCC a prognostic model for survival that includes molecular and clinical predictors is significantly more accurate than a standard clinical model using the combination of stage, histological grade and performance status.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Renal Cell / mortality. Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate


46. Szakmany T, Dodd M, Dempsey GA, Lowe D, Brown JS, Vaughan ED, Rogers SN: The influence of allogenic blood transfusion in patients having free-flap primary surgery for oral and oropharyngeal squamous cell carcinoma. Br J Cancer; 2006 Mar 13;94(5):647-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of allogenic blood transfusion in patients having free-flap primary surgery for oral and oropharyngeal squamous cell carcinoma.
  • The influence of perioperative blood transfusion in oral and oropharyngeal squamous cell carcinoma remains uncertain.
  • In all, 559 consecutive patients undergoing primary surgery for oral and oropharyngeal squamous cell carcinoma between 1992 and 2002 were included in this study.
  • Blood transfusion of 3 or more units might confer a worse prognosis in patients undergoing primary surgery for oral and oropharyngeal squamous cell carcinoma.
  • [MeSH-major] Blood Transfusion / adverse effects. Carcinoma, Squamous Cell / surgery. Mouth Neoplasms / surgery. Oropharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Immune System. Male. Middle Aged. Prognosis. Retrospective Studies. Surgical Flaps. Survival Analysis. Transplantation, Homologous. Treatment Outcome


47. Leheita O, Abed Elrazek NY, Younes S, Mahmoud AZ: Lymphocytes subsets in osteoarthritis versus rheumatoid arthritis. Egypt J Immunol; 2005;12(2):113-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Flow cytometric assessment of T cell (T helper, T cytotoxic), B cell, Natural killer cells and the CD4/CD8 ratio in the peripheral blood (PB) was carried out for both groups.
  • These findings reflect the similarity of immune cell profile in both RA and OA patients, and raised the possibility that abnormalities in T cell and its subsets may contribute to the pathogenesis of OA, and predispose to chronic progressive immune response in the synovial membrane (SM) with cartilage destruction.


48. Caetano J, Martinho A, Paiva A, Pais B, Valente C, Luxo C: Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV. J Virol; 2008 Aug;82(15):7567-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV.
  • To address these issues, hepatitis C virus (HCV)-specific CD8 T-cell responses were monitored, at the single-cell level, using HLA class I pentamers specific for HCV core and HCV NS3 epitopes, in 23 chronically infected patients during treatment with pegylated alpha interferon and ribavirin.
  • Patients who presented a sustained-response to therapy had stronger HCV-specific CD8 T-cell responses at all time points studied.
  • A better knowledge of the mechanisms underlying this impairment may be important for the development of new therapeutic strategies to maintain, restore, or increase CD8 T-cell effectiveness in chronic HCV infection.
  • [MeSH-minor] Adult. Epitopes / immunology. Female. Granzymes / analysis. Hepatitis C Antigens / immunology. Humans. Male. Middle Aged. Perforin / analysis. Recombinant Proteins. Viral Core Proteins / immunology. Viral Nonstructural Proteins / immunology

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis C (HCV).
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • Hazardous Substances Data Bank. RIBAVIRIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Feb;118(2):346-55 [10648463.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] J Exp Med. 2000 May 1;191(9):1499-512 [10790425.001]
  • [Cites] J Infect Dis. 2000 May;181(5):1528-36 [10823750.001]
  • [Cites] Science. 2000 Oct 6;290(5489):92-7 [11021806.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3094-101 [11049989.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):106-11 [11242051.001]
  • [Cites] J Virol. 2001 Jun;75(12):5550-8 [11356962.001]
  • [Cites] J Exp Med. 2001 Nov 19;194(10):1395-406 [11714747.001]
  • [Cites] Nat Med. 2002 Apr;8(4):379-85 [11927944.001]
  • [Cites] Nat Rev Immunol. 2002 Apr;2(4):251-62 [12001996.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):3447-58 [12218168.001]
  • [Cites] Science. 2003 Apr 11;300(5617):337-9 [12690201.001]
  • [Cites] J Exp Med. 2003 Jun 16;197(12):1645-55 [12810686.001]
  • [Cites] Science. 2003 Oct 24;302(5645):659-62 [14576438.001]
  • [Cites] Nat Rev Immunol. 2003 Dec;3(12):931-9 [14647475.001]
  • [Cites] Hepatology. 1996 Apr;23(4):909-16 [8666349.001]
  • [Cites] J Virol. 1996 Oct;70(10):7092-102 [8794355.001]
  • [Cites] J Exp Med. 1997 Nov 3;186(9):1407-18 [9348298.001]
  • [Cites] J Immunol. 1998 Aug 15;161(4):1947-53 [9712065.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1426-32 [9807989.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1485-92 [9819446.001]
  • [Cites] J Hepatol. 1999 Mar;30(3):376-82 [10190717.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5692-7 [10318946.001]
  • [Cites] Immunol Today. 1999 May;20(5):212-6 [10322299.001]
  • [Cites] J Hepatol. 1999 Sep;31(3):407-15 [10488697.001]
  • [Cites] J Viral Hepat. 2005 Mar;12(2):125-9 [15720526.001]
  • [Cites] J Virol. 2005 Oct;79(20):12979-88 [16189000.001]
  • [Cites] Antivir Ther. 2007;12(3):303-16 [17591020.001]
  • [Cites] Hepatology. 2000 Apr;31(4):1014-8 [10733560.001]
  • (PMID = 18480446.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Epitopes; 0 / Hepatitis C Antigens; 0 / Interferon-alpha; 0 / NS3 protein, hepatitis C virus; 0 / Recombinant Proteins; 0 / Viral Core Proteins; 0 / Viral Nonstructural Proteins; 0 / core protein p22, Hepatitis C virus; 0 / peginterferon alfa-2a; 0 / peginterferon alfa-2b; 126465-35-8 / Perforin; 30IQX730WE / Polyethylene Glycols; 49717AWG6K / Ribavirin; 76543-88-9 / interferon alfa-2a; 99210-65-8 / interferon alfa-2b; EC 3.4.21.- / Granzymes
  • [Other-IDs] NLM/ PMC2493325
  •  go-up   go-down


49. Huh YO, Medeiros LJ, Ravandi F, Konoplev S, Jorgensen JL, Miranda RN: T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases. Am J Clin Pathol; 2009 Mar;131(3):347-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases.
  • We describe 9 patients with T-cell large granular lymphocyte leukemia (T-LGL) who also had a myelodysplastic syndrome (MDS).
  • Immunophenotypic analysis showed a CD8+ T-cell population, and molecular analysis showed monoclonal T-cell receptor gene rearrangement in every case.
  • The MDS was classified as refractory cytopenia with multilineage dysplasia (RCMD, n = 5), refractory anemia (n = 2), RCMD with ringed sideroblasts (n = 1), and chronic myelomonocytic leukemia (n = 1).
  • [MeSH-major] Leukemia, Large Granular Lymphocytic / complications. Leukemia, Large Granular Lymphocytic / genetics. Leukemia, Large Granular Lymphocytic / pathology. Myelodysplastic Syndromes / complications. Myelodysplastic Syndromes / genetics. Myelodysplastic Syndromes / pathology
  • [MeSH-minor] Adult. Aged. Blotting, Southern. Female. Flow Cytometry. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Immunophenotyping. Lymphocyte Count. Male. Middle Aged. Polymerase Chain Reaction


50. Pertovaara M, Heliövaara M, Raitala A, Oja SS, Knekt P, Hurme M: The activity of the immunoregulatory enzyme indoleamine 2,3-dioxygenase is decreased in smokers. Clin Exp Immunol; 2006 Sep;145(3):469-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indoleamine 2,3-dioxygenase (IDO), an enzyme involved in the degradation of the essential amino acid tryptophan (trp) to its main metabolite kynurenine (kyn), suppresses T cell activity.
  • To this end we measured the ratio of kyn to trp, reflecting IDO activity, by reverse-phase high-performance liquid chromatography (HPLC) in 784 (464 female, 230 male) subjects of a population-based sample of the adult Finnish population.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Chromatography, High Pressure Liquid / methods. Cohort Studies. Cotinine / blood. Female. Humans. Inflammation. Kynurenine / analysis. Kynurenine / metabolism. Male. Middle Aged. Statistics, Nonparametric. T-Lymphocytes / immunology. Tryptophan / analysis. Tryptophan / metabolism

  • MedlinePlus Health Information. consumer health - Smoking.
  • Hazardous Substances Data Bank. Cotinine .
  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 2000 Jan;59(1):54-60 [10627428.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Feb;290(2):L222-31 [16126789.001]
  • [Cites] J Epidemiol Community Health. 2002 Mar;56(3):167-70 [11854334.001]
  • [Cites] Ann Rheum Dis. 2006 May;65(5):581-4 [16150789.001]
  • [Cites] Ann Rheum Dis. 2006 May;65(5):666-70 [16166103.001]
  • [Cites] Clin Chem. 2002 Mar;48(3):579-81 [11861457.001]
  • [Cites] Nat Rev Immunol. 2002 May;2(5):372-7 [12033743.001]
  • [Cites] Arthritis Rheum. 2002 Aug15;47(4):403-7 [12209487.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):5809-13 [12794104.001]
  • [Cites] Immunology. 2003 Jul;109(3):329-30 [12807476.001]
  • [Cites] Immunology. 2003 Jul;109(3):365-73 [12807482.001]
  • [Cites] Am J Respir Cell Mol Biol. 2004 Feb;30(2):202-11 [12920055.001]
  • [Cites] Clin Immunol. 2004 Oct;113(1):47-55 [15380529.001]
  • [Cites] Nat Rev Immunol. 2004 Oct;4(10):762-74 [15459668.001]
  • [Cites] Arthritis Rheum. 2004 Oct;50(10):3085-92 [15476204.001]
  • [Cites] Rheumatology (Oxford). 2004 Nov;43(11):1424-8 [15328423.001]
  • [Cites] Int J Cancer. 1979 May 15;23(5):603-9 [457307.001]
  • [Cites] Ann Rheum Dis. 1990 Oct;49(10):753-6 [2241263.001]
  • [Cites] Clin Chem. 1991 Nov;37(11):1989-93 [1934477.001]
  • [Cites] J Rheumatol. 1993 Nov;20(11):1830-5 [8308766.001]
  • [Cites] Environ Health Perspect. 1999 May;107 Suppl 2:349-55 [10350520.001]
  • [Cites] Immunol Today. 1999 Oct;20(10):469-73 [10500295.001]
  • [Cites] Arch Intern Med. 2004 Nov 8;164(20):2206-16 [15534156.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2684-91 [16081845.001]
  • [Cites] Clin Exp Immunol. 2005 Oct;142(1):155-61 [16178870.001]
  • [Cites] Inflamm Bowel Dis. 2005 Dec;11(12):1092-6 [16306772.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2005 Nov;2(11):536-44 [16355159.001]
  • [Cites] Mol Immunol. 2006 Mar;43(7):1054-6 [15992929.001]
  • [Cites] Redox Rep. 1999;4(5):199-220 [10731095.001]
  • (PMID = 16907915.001).
  • [ISSN] 0009-9104
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase; 343-65-7 / Kynurenine; 8DUH1N11BX / Tryptophan; K5161X06LL / Cotinine
  • [Other-IDs] NLM/ PMC1809700
  •  go-up   go-down


51. Goodwin R, Ding K, Seymour L, LeMaître A, Arnold A, Shepherd FA, Dediu M, Ciuleanu T, Fenton D, Zukin M, Walde D, Laberge F, Vincent M, Ellis PM, Laurie SA, NCIC Clinical Trials Group, Kingston, Ontario, Canada: Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol; 2010 Nov;21(11):2220-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
  • PATIENTS AND METHODS: BR24 was a double-blind placebo-controlled phase II trial of carboplatin/paclitaxel chemotherapy with either daily oral cediranib or placebo in patients (n = 296) with advanced non-small-cell lung cancer (NSCLC).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20427348.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Placebos; 0 / Quinazolines; BG3F62OND5 / Carboplatin; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; NQU9IPY4K9 / cediranib; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


52. Fletcher MA, Zeng XR, Maher K, Levis S, Hurwitz B, Antoni M, Broderick G, Klimas NG: Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS One; 2010 May 25;5(5):e10817
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26.
  • BACKGROUND: Chronic Fatigue Syndrome (CFS) studies from our laboratory and others described decreased natural killer cell cytotoxicity (NKCC) and elevated proportion of lymphocytes expressing the activation marker, dipeptidyl peptidase IV (DPPIV) also known as CD26.
  • NK cell function was measured with a bioassay, using K562 cells and (51)Cr release.
  • There was no significant difference in NK cell counts between cases and controls.
  • Abnormalities in DPPIV/CD26 and in NK cell function have particular relevance to the possible role of infection in the initiation and/or the persistence of CFS.

  • Genetic Alliance. consumer health - Chronic fatigue syndrome.
  • MedlinePlus Health Information. consumer health - Chronic Fatigue Syndrome.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drugs. 2002;62(17):2433-46 [12421101.001]
  • [Cites] Science. 2009 Oct 23;326(5952):585-9 [19815723.001]
  • [Cites] Eur J Immunol. 2003 Jun;33(6):1519-27 [12778469.001]
  • [Cites] Psychiatry Clin Neurosci. 2003 Aug;57(4):361-8 [12839515.001]
  • [Cites] Arch Intern Med. 2003 Jul 14;163(13):1530-6 [12860574.001]
  • [Cites] J Psychosom Res. 2003 Aug;55(2):79-90 [12932505.001]
  • [Cites] BMC Health Serv Res. 2003 Dec 31;3(1):25 [14702202.001]
  • [Cites] Diagn Clin Immunol. 1987;5(2):69-81 [3113759.001]
  • [Cites] J Immunol. 1987 Nov 15;139(10):3306-13 [2824604.001]
  • [Cites] J Clin Microbiol. 1990 Jun;28(6):1403-10 [2166084.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2922-6 [1672770.001]
  • [Cites] Lancet. 1991 Sep 21;338(8769):707-12 [1679864.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5516s-5518s; discussion 5518s-5521s [1394166.001]
  • [Cites] Ann Intern Med. 1993 Feb 15;118(4):241-5 [8420441.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Clin Infect Dis. 1994 Jan;18 Suppl 1:S136-41 [8148441.001]
  • [Cites] Clin Exp Immunol. 1994 Nov;98(2):252-6 [7955530.001]
  • [Cites] Ann Intern Med. 1994 Dec 15;121(12):953-9 [7978722.001]
  • [Cites] J Psychiatr Res. 1997 Jan-Feb;31(1):115-22 [9201653.001]
  • [Cites] Arch Intern Med. 1999 Oct 11;159(18):2129-37 [10527290.001]
  • [Cites] Brain Behav Immun. 2005 Mar;19(2):91-103 [15664781.001]
  • [Cites] Am J Pathol. 2005 Feb;166(2):433-42 [15681827.001]
  • [Cites] Clin Exp Immunol. 2005 Dec;142(3):505-11 [16297163.001]
  • [Cites] PLoS One. 2010;5(1):e8519 [20066031.001]
  • [Cites] Clin Exp Rheumatol. 2010 Jan-Feb;28(1):19-24 [20346233.001]
  • [Cites] Virology. 2006 Mar 1;346(1):205-18 [16321417.001]
  • [Cites] J Psychosom Res. 2006 Jun;60(6):559-66 [16731230.001]
  • [Cites] Health Care Women Int. 2006 Aug;27(7):615-26 [16844674.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Dec;21(12):1789-93 [17074015.001]
  • [Cites] J Clin Virol. 2006 Dec;37 Suppl 1:S33-8 [17276366.001]
  • [Cites] Med Sci Monit. 2007 Jul;13(7):CS88-92 [17599032.001]
  • [Cites] JAMA. 2007 Jul 11;298(2):194-206 [17622601.001]
  • [Cites] Disabil Rehabil. 2008;30(16):1185-91 [17852256.001]
  • [Cites] Genomics. 2008 Dec;92(6):393-9 [18775774.001]
  • [Cites] Vasc Health Risk Manag. 2008;4(4):753-68 [19065993.001]
  • [Cites] J Health Psychol. 2003 Jul;8(4):459-64 [19127712.001]
  • [Cites] Brain Behav Immun. 2009 Mar;23(3):327-37 [19111923.001]
  • [Cites] Immunology. 2009 Mar;126(3):346-53 [18657205.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):479-86 [19748065.001]
  • [Cites] Clin Sci (Lond). 2010 Jan;118(2):125-35 [19469714.001]
  • [Cites] Neuroimmunomodulation. 2002-2003;10(3):134-41 [12481153.001]
  • (PMID = 20520837.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI065723; United States / NIAID NIH HHS / AI / R01AI065723; United States / NHLBI NIH HHS / HL / R01 HL65668; United States / NIAID NIH HHS / AI / U01 AI459940; United States / NIAAA NIH HHS / AA / R21AA016635; United States / NIAMS NIH HHS / AR / R01 AR048932; United States / NIAMS NIH HHS / AR / R01 AR48932-01A1; United States / NHLBI NIH HHS / HL / R01 HL065668
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; EC 3.4.14.5 / DPP4 protein, human; EC 3.4.14.5 / Dipeptidyl Peptidase 4
  • [Other-IDs] NLM/ PMC2876037
  •  go-up   go-down


53. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA: Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood; 2009 Jul 16;114(3):535-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
  • Gene therapy of human cancer using genetically engineered lymphocytes is dependent on the identification of highly reactive T-cell receptors (TCRs) with antitumor activity.
  • [MeSH-major] Antigens, Neoplasm / immunology. Genetic Therapy / methods. Melanoma / therapy. Receptors, Antigen, T-Cell / administration & dosage
  • [MeSH-minor] Adoptive Transfer / adverse effects. Adoptive Transfer / methods. Adult. Animals. Autoantigens / immunology. Female. Genetic Vectors. Hearing Loss / etiology. Humans. Lymphocyte Transfusion / adverse effects. Lymphocyte Transfusion / methods. Lymphocytes / metabolism. Male. Melanocytes / immunology. Mice. Mice, Transgenic. Middle Aged. T-Cell Antigen Receptor Specificity. Transduction, Genetic. Transplantation, Autologous. Treatment Outcome. Uveitis / etiology

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):5799-808 [16237072.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):35-45 [12509765.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1290-8 [12393508.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):332-42 [12843795.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4 [8421711.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3515-9 [8170938.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6458-62 [8022805.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):11993-7 [8618830.001]
  • [Cites] J Immunol. 2004 Dec 15;173(12):7125-30 [15585832.001]
  • [Cites] J Clin Invest. 2004 Dec;114(12):1774-81 [15599402.001]
  • [Cites] J Immunol. 2005 Apr 1;174(7):4415-23 [15778407.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2346-57 [15800326.001]
  • [Cites] Hum Gene Ther. 2005 Apr;16(4):457-72 [15871677.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Nature. 2001 May 17;411(6835):380-4 [11357146.001]
  • [Cites] Immunol Rev. 2006 Feb;209:290-6 [16448550.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):383-93 [16622476.001]
  • [Cites] Science. 2006 Oct 6;314(5796):126-9 [16946036.001]
  • [Cites] J Immunol. 2006 Nov 1;177(9):6548-59 [17056587.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Dec;3(12):668-81 [17139318.001]
  • [Cites] Annu Rev Immunol. 2007;25:243-65 [17129181.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35 [17855649.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2620-30 [17507664.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):299-308 [18354418.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8061-6 [18523011.001]
  • [Cites] Curr Eye Res. 2008 Jul;33(7):517-23 [18600484.001]
  • [Cites] Gene Ther. 2008 Nov;15(21):1411-23 [18496571.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5233-9 [18809613.001]
  • [Cites] Nat Med. 2008 Nov;14(11):1264-70 [18978797.001]
  • [Cites] Clin Cancer Res. 2009 Jan 1;15(1):169-80 [19118044.001]
  • [CommentIn] Expert Rev Vaccines. 2010 Apr;9(4):359-63 [20370546.001]
  • (PMID = 19451549.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantigens; 0 / Receptors, Antigen, T-Cell
  • [Other-IDs] NLM/ PMC2929689
  •  go-up   go-down


54. Kreft A, Holtmann H, Schad A, Kirkpatrick CJ: Detection of residual leukemic blasts in adult patients with acute T-lymphoblastic leukemia using bone marrow trephine biopsies: comparison of fluorescent immunohistochemistry with conventional cytologic and flow-cytometric analysis. Pathol Res Pract; 2010 Aug 15;206(8):560-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of residual leukemic blasts in adult patients with acute T-lymphoblastic leukemia using bone marrow trephine biopsies: comparison of fluorescent immunohistochemistry with conventional cytologic and flow-cytometric analysis.
  • Evaluation of remission in adult acute lymphoblastic leukemia (ALL) normally relies on cytologic evaluation and flow-cytometric analysis.
  • [MeSH-major] Bone Marrow / pathology. Flow Cytometry. Fluorescent Antibody Technique. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Biopsy. Cell Separation. Cytological Techniques. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20413226.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. Korosec P, Rijavec M, Silar M, Kern I, Kosnik M, Osolnik K: Deficiency of pulmonary Valpha24 Vbeta11 natural killer T cells in corticosteroid-naïve sarcoidosis patients. Respir Med; 2010 Apr;104(4):571-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invariant natural killer T (NKT) cells might contribute to the amplified and prolonged T-cell immune response that characterizes sarcoidosis.
  • Moreover, lower invariant NKT cell frequencies in patients with sarcoidosis significantly correlated with exaggerated BALF lymphocytosis and CD4 T cell responses.
  • [MeSH-major] Bronchoalveolar Lavage Fluid / cytology. Natural Killer T-Cells / cytology. Receptors, Antigen, T-Cell / immunology. Sarcoidosis, Pulmonary / immunology
  • [MeSH-minor] Adult. Aged. CD4-CD8 Ratio. Case-Control Studies. Female. Flow Cytometry. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Sarcoidosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19954940.001).
  • [ISSN] 1532-3064
  • [Journal-full-title] Respiratory medicine
  • [ISO-abbreviation] Respir Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell; 0 / Valpha24 protein, human
  •  go-up   go-down


56. Takimoto N, Kusakabe T, Tsuda M: Origin of the vertebrate visual cycle. Photochem Photobiol; 2007 Mar-Apr;83(2):242-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mammalian visual cycle takes place in photoreceptor cells and retinal pigment epithelial (RPE) cells, while that of cephalopods is completed within a photoreceptor cell.
  • Ci-RPE65 is expressed in the neural complex, a photoreceptor organ of the adult ascidian, at a level comparable with that of Ci-opsin3 and Ci-CRALBP.
  • These results suggest that the larval visual cycle uses Ci-opsin3 as a photoisomerase, while the visual cycle of the adult photoreceptors is RPE65-dependent.
  • The colocalization of visual cycle proteins in the photoreceptor cells suggest that ascidian visual cycle takes place in a photoreceptor cell as seen in the cephalopod visual cycle.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930093.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Eye Proteins; 0 / Retinal Pigments
  • [Number-of-references] 52
  •  go-up   go-down


57. Saito A, Miyazawa Y, Isoda A, Hatsumi N, Matsumoto M, Kojima M, Sawamura M: [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)]. Rinsho Ketsueki; 2008 Feb;49(2):82-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)].
  • We retrospectively analyzed the clinical course and prognosis of 11 patients with angioimmunoblastic T-cell Lymphoma (AILT).
  • As the initial therapy, 10 patients received combination chemotherapy and only 1 patient received autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341037.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


58. Behfar A, Yamada S, Crespo-Diaz R, Nesbitt JJ, Rowe LA, Perez-Terzic C, Gaussin V, Homsy C, Bartunek J, Terzic A: Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol; 2010 Aug 24;56(9):721-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adult stem cells, delivered in their naïve state, demonstrate a limited benefit in patients with ischemic heart disease.
  • Engraftment into murine hearts was associated with increased human-specific nuclear, sarcomeric, and gap junction content along with induction of myocardial cell cycle activity.

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Attack.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Nature. 2002 Jul 4;418(6893):41-9 [12077603.001]
  • [Cites] J Am Coll Cardiol. 2002 May 1;39(9):1508-12 [11985915.001]
  • [Cites] Circ Res. 2003 Mar 7;92(4):444-52 [12600892.001]
  • [Cites] Cardiovasc Res. 2003 May 1;58(2):423-34 [12757876.001]
  • [Cites] Circulation. 2003 Jun 3;107(21):2733-40 [12742992.001]
  • [Cites] Genes Dev. 2003 Aug 15;17(16):1937-56 [12893779.001]
  • [Cites] Cell. 2003 Sep 19;114(6):763-76 [14505575.001]
  • [Cites] Circ Res. 2004 Oct 29;95(9):911-21 [15472116.001]
  • [Cites] Development. 1997 Jun;124(12):2387-95 [9199365.001]
  • [Cites] J Mol Cell Cardiol. 1997 Jun;29(6):1525-39 [9220339.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):572-83 [15765139.001]
  • [Cites] Stem Cells. 2006 Feb;24(2):462-71 [16109759.001]
  • [Cites] Nature. 2006 Jun 29;441(7097):1097-9 [16810246.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1274-7 [16990391.001]
  • [Cites] J Am Coll Cardiol. 2006 Nov 21;48(10):2116-24 [17113001.001]
  • [Cites] Circulation. 2007 Feb 20;115(7):896-908 [17283259.001]
  • [Cites] J Exp Med. 2007 Feb 19;204(2):405-20 [17283208.001]
  • [Cites] Arch Intern Med. 2007 May 28;167(10):989-97 [17533201.001]
  • [Cites] Clin Pharmacol Ther. 2007 Sep;82(3):320-4 [17637785.001]
  • [Cites] Stem Cells. 2008 Feb;26(2):387-400 [17991915.001]
  • [Cites] Nature. 2008 Feb 21;451(7181):937-42 [18288183.001]
  • [Cites] Cell. 2008 Feb 22;132(4):537-43 [18295570.001]
  • [Cites] J Am Coll Cardiol. 2008 Mar 4;51(9):933-43 [18308163.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10(3):338-45 [18297060.001]
  • [Cites] Circ Res. 2008 Mar 14;102(5):597-606 [18202313.001]
  • [Cites] Nature. 2008 May 15;453(7193):322-9 [18480813.001]
  • [Cites] Circ Res. 2008 Jun 6;102(11):1319-30 [18535269.001]
  • [Cites] Circulation. 2009 Sep 15;120(11 Suppl):S247-54 [19752375.001]
  • [Cites] Circulation. 2009 Sep 22;120(12):1075-83, 7 p following 1083 [19738142.001]
  • [Cites] Curr Opin Organ Transplant. 2008 Feb;13(1):36-43 [18660705.001]
  • [Cites] FASEB J. 2002 Oct;16(12):1558-66 [12374778.001]
  • [Cites] J Am Coll Cardiol. 2009 Dec 8;54(24):2277-86 [19958962.001]
  • [Cites] Stem Cells. 2008 Sep;26(9):2201-10 [18599808.001]
  • [Cites] J Mol Cell Cardiol. 2008 Oct;45(4):514-22 [18304573.001]
  • [Cites] J Mol Cell Cardiol. 2008 Oct;45(4):523-9 [18835562.001]
  • [Cites] Nat Rev Immunol. 2008 Sep;8(9):726-36 [19172693.001]
  • [Cites] Stem Cells. 2009 Jul;27(7):1697-705 [19544428.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14022-7 [19666564.001]
  • [Cites] Genome Biol. 2008;9(1):R6 [18184438.001]
  • [Cites] Nature. 2008 Jul 3;454(7200):109-13 [18568026.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1282-6 [11062543.001]
  • [Cites] Nature. 2001 Apr 5;410(6829):701-5 [11287958.001]
  • [Cites] Cell. 2001 Sep 21;106(6):709-21 [11572777.001]
  • [CommentIn] J Am Coll Cardiol. 2010 Aug 24;56(9):735-7 [20723803.001]
  • (PMID = 20723802.001).
  • [ISSN] 1558-3597
  • [Journal-full-title] Journal of the American College of Cardiology
  • [ISO-abbreviation] J. Am. Coll. Cardiol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL083439-02; United States / NHLBI NIH HHS / HL / R01 HL085208-05; United States / NHLBI NIH HHS / HL / HL085208-04; United States / NHLBI NIH HHS / HL / R01 HL083439-02; United States / NHLBI NIH HHS / HL / R01 HL083439-04; United States / NHLBI NIH HHS / HL / R01 HL085208-01A1; United States / NHLBI NIH HHS / HL / R01 HL085208-02; United States / NHLBI NIH HHS / HL / R01 HL085208; United States / NHLBI NIH HHS / HL / HL083439-03; United States / NHLBI NIH HHS / HL / HL83439; United States / NHLBI NIH HHS / HL / R01 HL083439-05; United States / NHLBI NIH HHS / HL / R01 HL083439-01; United States / NHLBI NIH HHS / HL / HL85208; United States / NHLBI NIH HHS / HL / HL085208-03; United States / NHLBI NIH HHS / HL / HL083439-01; United States / NHLBI NIH HHS / HL / R01 HL083439; United States / NHLBI NIH HHS / HL / R01 HL083439-03; United States / NHLBI NIH HHS / HL / HL083439-04; United States / NHLBI NIH HHS / HL / R01 HL085208-04; United States / NHLBI NIH HHS / HL / HL085208-01A1; United States / NHLBI NIH HHS / HL / HL085208-05; United States / NHLBI NIH HHS / HL / HL085208-02; United States / NHLBI NIH HHS / HL / R01 HL085208-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biological Factors; 0 / Homeodomain Proteins; 0 / MADS Domain Proteins; 0 / MEF2 Transcription Factors; 0 / MEF2C protein, human; 0 / Myogenic Regulatory Factors; 0 / NKX2-5 protein, human; 0 / T-Box Domain Proteins; 0 / T-box transcription factor 5; 0 / Transcription Factors
  • [Other-IDs] NLM/ NIHMS230874; NLM/ PMC2932958
  •  go-up   go-down


59. Sayitoğlu M, Ar MC, Hatırnaz Ö, Öngören Ş, Üre Ü, Başlar Z, Sırma S, Aydın Y, Özbek U, Ferhanoğlu B: Minimal Residual Disease (MRD) Detection with Translocations and T-Cell Receptor and Immunoglobulin Gene Rearrangements in Adult Acute Lymphoblastic Leukaemia Patients: A Pilot Study. Turk J Haematol; 2008 Sep 5;25(3):124-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal Residual Disease (MRD) Detection with Translocations and T-Cell Receptor and Immunoglobulin Gene Rearrangements in Adult Acute Lymphoblastic Leukaemia Patients: A Pilot Study.
  • Break-point fusion regions of leukaemia related chromosomal aberrations and rearranged immunoglobulin (Ig) and T cell-receptor (TCR) genes, which can be detected by polymerase chain reaction (PCR), are used as leukaemia specific markers in genetic studies of MRD.
  • MRD monitoring is progressively getting to be a more important predictive factor in adult ALL patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27264703.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


61. Lindeborg E, Kumagai-Braesch M, Möller E: Phenotypic and functional characterization of human T cell clones indirectly activated against adult pig islet cells. Xenotransplantation; 2006 Jan;13(1):41-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic and functional characterization of human T cell clones indirectly activated against adult pig islet cells.
  • IgG1 antibody production is believed to be dependent upon T cell help.
  • Therefore, as a natural continuation of our work aimed at characterizing the xenoimmune antibody response against pig islet cells, we have also examined the T cell response.
  • T cell reactivity against islet cells is believed to result from indirect antigen presentation, and our in vitro study was designed to mimic the response in vivo.
  • The main purpose of this study was to characterize the phenotype, the immunological specificity and the functional capacity of indirectly activated T cell clones, reactive against pig islet cell antigens.
  • MATERIALS AND METHODS: Human T cell clones, activated against pig islet cells in the presence of autologous antigen-presenting cells, were produced from limiting dilutions of bulk cultures.
  • Clonality was investigated by T cell receptor Vbeta (TcRVbeta) expression analysis.
  • The cytotoxic capacity of the clones was assessed using standard cell-mediated lysis tests and different porcine and human target cells.
  • RESULTS: Nineteen CD4+ TcRValphabeta+ T cell clones were recovered.
  • The immunological specificity differed between clones; some were specifically reactive against pig islet cell antigens, while others were reactive with antigens present on a variety of pig cells.
  • None of the T cell clones were cytotoxic against pig islet cells, but two clones were cytotoxic against pig phytohemagglutinin (PHA)-blasts.
  • CONCLUSION: The analysis of several, indirectly activated, human CD4+ T cell clones shows that the response against pig islet cells is heterogeneous both with regard to immunological specificity and functional characteristics.
  • [MeSH-minor] Animals. Cell Proliferation. Cells, Cultured. Humans. Islets of Langerhans Transplantation. Phenotype. Receptors, Antigen, T-Cell / metabolism. Swine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16497211.001).
  • [ISSN] 0908-665X
  • [Journal-full-title] Xenotransplantation
  • [ISO-abbreviation] Xenotransplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


62. Sharma PK, Saha PK, Singh A, Sharma SK, Ghosh B, Mitra DK: FoxP3+ regulatory T cells suppress effector T-cell function at pathologic site in miliary tuberculosis. Am J Respir Crit Care Med; 2009 Jun 1;179(11):1061-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FoxP3+ regulatory T cells suppress effector T-cell function at pathologic site in miliary tuberculosis.
  • RATIONALE: The inadequacy of effector T-cell response in containment of tubercle bacilli is believed to result in the development of disseminated forms of tuberculosis (TB), such as miliary tuberculosis (MTB).
  • OBJECTIVES: To (1) enumerate the frequency of Treg cells in bronchoalveolar lavage (BAL) fluid of patients with MTB and compare with that of peripheral blood, (2) study the role of Treg cells in suppression of local T-cell response, and (3) study the selective recruitment of Treg cells at the local disease site(s).
  • METHODS: Flow cytometry, reverse transcriptase polymerase chain reaction, and 3-(4,5-dimethylthythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)-based cell proliferation assay.
  • Importantly, FoxP3(+) Treg cells obtained from the BAL of patients with MTB predominantly produced IL-10 and could suppress the autologous T-cell proliferation in response to M. tuberculosis antigen.
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Female. Humans. Interleukin-10 / metabolism. Lymphocyte Count. Male. Middle Aged. Th1 Cells / metabolism. Young Adult

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246720.001).
  • [ISSN] 1535-4970
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / IL10 protein, human; 130068-27-8 / Interleukin-10
  •  go-up   go-down


63. Wang Y, Meng J, Wang X, Liu S, Shu Q, Gao L, Ju Y, Zhang L, Sun W, Ma C: Expression of human TIM-1 and TIM-3 on lymphocytes from systemic lupus erythematosus patients. Scand J Immunol; 2008 Jan;67(1):63-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The T-cell immunoglobulin- and mucin-domain-containing molecules (TIMs) comprise a new family of cell surface molecules expressed on T cells.
  • TIM-1 is suggested to act as a co-stimulatory molecule for all T cells, but with potentially stronger effects on Th2 than Th1 cells and is associated with Th2-related immune diseases.
  • However, the expression of TIM-3 ligand, galectin-9 increased in SLE patients indicating an enhanced engagement of TIM-3 with its ligand in SLE, which may result in a decreased regulatory T-cell function as shown by the decreased expression of FoxP3 and TGF-beta1 in SLE.
  • [MeSH-minor] Adult. Cells, Cultured. Cytokines / biosynthesis. Cytokines / genetics. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18052965.001).
  • [ISSN] 1365-3083
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / HAVCR1 protein, human; 0 / HAVCR2 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Receptors, Virus
  •  go-up   go-down


64. Okubo T, Clark C, Hogan BL: Cell lineage mapping of taste bud cells and keratinocytes in the mouse tongue and soft palate. Stem Cells; 2009 Feb;27(2):442-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell lineage mapping of taste bud cells and keratinocytes in the mouse tongue and soft palate.
  • The epithelium of the mouse tongue and soft palate consists of at least three distinct epithelial cell populations: basal cells, keratinized cells organized into filiform and fungiform papillae, and taste receptor cells present in tight clusters known as taste buds in the fungiform and circumvallate papillae and soft palate.
  • All three cell types develop from the simple epithelium of the embryonic tongue and palate, and are continually replaced in the adult by cell turnover.
  • Previous studies using pulse-chase tritiated thymidine labeling in the adult mouse provided evidence for a high rate of cell turnover in the keratinocytes (5-7 days) and taste buds (10 days).
  • Here, we make use of a tamoxifen-inducible K14-CreER transgene and the ROSA26 LacZ reporter allele to lineage trace the mature keratinocytes and taste bud cells of the early postnatal and adult mouse tongue and soft palate.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19038788.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL071303; United States / NHLBI NIH HHS / HL / R37 HL071303; United States / NHLBI NIH HHS / HL / HL071303
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Keratin-14; 0 / Keratin-8; 0 / Phosphoproteins; 0 / SOXB1 Transcription Factors; 0 / Sox2 protein, mouse; 0 / Trans-Activators; 0 / Trp63 protein, mouse; 094ZI81Y45 / Tamoxifen
  • [Other-IDs] NLM/ NIHMS662508; NLM/ PMC4337989
  •  go-up   go-down


65. Takeshita K, Satoh M, Ii M, Silver M, Limbourg FP, Mukai Y, Rikitake Y, Radtke F, Gridley T, Losordo DW, Liao JK: Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res; 2007 Jan 5;100(1):70-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Notch receptors are important mediators of cell fate during embryogenesis, but their role in adult physiology, particularly in postnatal angiogenesis, remains unknown.
  • Indeed, inhibition of gamma-secretase activity leads to decreased angiogenesis and inhibits VEGF-induced endothelial cell proliferation, migration, and survival.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1343-52 [10837027.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8501-10 [16951162.001]
  • [Cites] Circulation. 2000 Oct 24;102(17):2124-30 [11044431.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Jan;22(1):108-14 [11788469.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):10760-6 [11784722.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1393-403 [11943724.001]
  • [Cites] Circ Res. 2002 Jun 28;90(12):1243-50 [12089061.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):127-36 [12110173.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):14-25 [12482957.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):543-53 [12615665.001]
  • [Cites] Nature. 2003 May 22;423(6938):435-9 [12761548.001]
  • [Cites] J Biol Chem. 2003 Jul 4;278(27):24277-84 [12697771.001]
  • [Cites] Mech Dev. 2003 Jun;120(6):657-67 [12834865.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5726-37 [12897144.001]
  • [Cites] Nat Rev Genet. 2003 Sep;4(9):710-20 [12951572.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1417-28 [14507649.001]
  • [Cites] Curr Opin Neurobiol. 2004 Jun;14(3):379-83 [15194119.001]
  • [Cites] Genes Dev. 2004 Oct 15;18(20):2469-73 [15466160.001]
  • [Cites] Dev Biol. 1991 Nov;148(1):51-62 [1936575.001]
  • [Cites] Genes Dev. 1994 Mar 15;8(6):707-19 [7926761.001]
  • [Cites] Cell. 1994 Oct 21;79(2):273-82 [7954795.001]
  • [Cites] Development. 1995 May;121(5):1533-45 [7789282.001]
  • [Cites] Nature. 1995 Sep 28;377(6547):355-8 [7566092.001]
  • [Cites] Neuron. 1996 Jul;17(1):181-90 [8755489.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1379-86 [9358764.001]
  • [Cites] Nature. 1998 May 28;393(6683):382-6 [9620803.001]
  • [Cites] J Clin Invest. 1998 Jun 1;101(11):2567-78 [9616228.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):7423-31 [9819428.001]
  • [Cites] Trends Cell Biol. 1998 Nov;8(11):447-53 [9854312.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):518-22 [10206645.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Nat Med. 1999 May;5(5):495-502 [10229225.001]
  • [Cites] Circulation. 2005 Apr 12;111(14):1826-32 [15809373.001]
  • [Cites] Eur J Pharmacol. 2005 May 2;514(1):1-15 [15878319.001]
  • [Cites] Cell. 2006 Jan 13;124(1):161-73 [16413489.001]
  • [Cites] Nature. 2000 Jun 22;405(6789):966-70 [10879540.001]
  • (PMID = 17158336.001).
  • [ISSN] 1524-4571
  • [Journal-full-title] Circulation research
  • [ISO-abbreviation] Circ. Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P01 NS010828; United States / NHLBI NIH HHS / HL / R01 HL052233-12; United States / NHLBI NIH HHS / HL / R01 HL052233-11; United States / NHLBI NIH HHS / HL / HL080187-01A1; United States / NHLBI NIH HHS / HL / R01 HL080187-03; United States / NINDS NIH HHS / NS / P01 NS010828-330036; United States / NHLBI NIH HHS / HL / R01 HL080187-02; United States / NHLBI NIH HHS / HL / HL70274; United States / NHLBI NIH HHS / HL / R01 HL070274-05; United States / NIDDK NIH HHS / DK / R01 DK062729-05; United States / NHLBI NIH HHS / HL / HL052233; United States / NHLBI NIH HHS / HL / R01 HL070274-04; United States / NINDS NIH HHS / NS / NS010828-330036; United States / NHLBI NIH HHS / HL / R01 HL052233; United States / NIDDK NIH HHS / DK / R01 DK062729; United States / NHLBI NIH HHS / HL / HL080187-02; United States / NHLBI NIH HHS / HL / HL080187; United States / NHLBI NIH HHS / HL / R01 HL070274; United States / NHLBI NIH HHS / HL / HL080187-03; United States / NHLBI NIH HHS / HL / R01 HL080187; United States / NHLBI NIH HHS / HL / R01 HL080187-01A1; United States / NIDDK NIH HHS / DK / R01 DK062729-04; United States / NHLBI NIH HHS / HL / HL052233-11
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Notch1 protein, mouse; 0 / Receptor, Notch1; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.- / Amyloid Precursor Protein Secretases
  • [Other-IDs] NLM/ NIHMS84976; NLM/ PMC2615564
  •  go-up   go-down


66. Iannone F, Riccardi MT, Guiducci S, Bizzoca R, Cinelli M, Matucci-Cerinic M, Lapadula G: Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis; 2008 Aug;67(8):1121-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As endothelial activation markers, serum soluble P-selectin, platelet/endothelial cell adhesion molecule (PECAM)-1, vascular cell adhesion molecule (VCAM)-1, intercellular adhesion molecule (ICAM)-1 and von Willebrand factor (vWF) antigen were assessed by ELISA.
  • In patients with SSc-PAH, T cell subsets and soluble endothelial markers were assessed at baseline and after 6 and 12 months of bosentan therapy.
  • CONCLUSIONS: This study confirms that endothelial activation occurs in SSc, and suggests that changes in the T cell/endothelium interplay take place in SSc-associated PAH.
  • Bosentan seems to be able to hamper these changes and restore T cell functions in these patients.
  • [MeSH-major] Antihypertensive Agents / pharmacology. Cell Adhesion Molecules / metabolism. Endothelin-1 / antagonists & inhibitors. Hypertension, Pulmonary / metabolism. Scleroderma, Systemic / metabolism. Sulfonamides / pharmacology. T-Lymphocytes / drug effects
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antibodies, Antinuclear / immunology. Antigens, CD3 / analysis. Autoantibodies / immunology. Case-Control Studies. Centromere / immunology. Female. Humans. Integrin alpha4beta1 / analysis. Integrin alpha4beta1 / blood. L-Selectin / analysis. L-Selectin / blood. Lymphocyte Function-Associated Antigen-1 / analysis. Lymphocyte Function-Associated Antigen-1 / blood. Male. Middle Aged


67. Meehan M, Melvin A, Gallagher E, Smith J, McGoldrick A, Moss C, Goossens S, Harrison M, Kay E, Fitzpatrick J, Dervan P, Mc Cann A: Alpha-T-catenin (CTNNA3) displays tumour specific monoallelic expression in urothelial carcinoma of the bladder. Genes Chromosomes Cancer; 2007 Jun;46(6):587-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The allelic expression pattern of CTNNA3 in adult human cancer is unknown and warrants investigation as CTNNA3 stabilizes cellular adherence, a feature which if compromised could enable cells to acquire an increased capability to detach and invade.
  • A total of 96 samples were analyzed and included 22 paired normal and tumor UCB cases, 38 formalin fixed paraffin embedded (FFPE) UCB samples consisting of 18 noninvasive pTa tumors and 20 lamina propria invasive pT1 tumors and 14 cell lines of various lineages.
  • [MeSH-minor] Cell Line. Cohort Studies. Female. Heterozygote. Humans. Male. Neoplasm Staging. Risk

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17366617.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNA3 protein, human; 0 / alpha Catenin
  •  go-up   go-down


68. Sidat MM, Mijch AM, Lewin SR, Hoy JF, Hocking J, Fairley CK: Incidence of putative HIV superinfection and sexual practices among HIV-infected men who have sex with men. Sex Health; 2008 Mar;5(1):61-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Those clients with sudden, unexplained and sustained declines in CD4 T-cell counts and increases in plasma HIV RNA were considered as being putatively superinfected with HIV and were recruited as cases, whereas those without these features were recruited as controls (four per case) to answer a self-administered questionnaire.
  • Cases had an annual decline in CD4 T-cell counts of 201 cells microL(-1) compared with 9 cells microL(-1) for controls.
  • [MeSH-minor] Adult. Case-Control Studies. Cohort Studies. Confidence Intervals. Humans. Incidence. Male. Middle Aged. Odds Ratio. Retrospective Studies. Sexual Partners

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361856.001).
  • [ISSN] 1448-5028
  • [Journal-full-title] Sexual health
  • [ISO-abbreviation] Sex Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


69. Martorell-Calatayud A, Hernández-Martín A, Colmenero I, Vañó-Galván S, López-Obregón C, Armand A, Gambra Arzoz M, Torrelo A: [Lymphomatoid papulosis in children: report of 9 cases and review of the literature]. Actas Dermosifiliogr; 2010 Oct;101(8):693-701
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lymphomatoid papulosis is a rare lymphoproliferative T cell CD30+ disease with excellent prognosis which affects almost exclusively adult patients, being rarely in the childhood; thus the clinic and pathologic spectrum and the risk of evolution to another type of lymphoma are not well defined in the pediatric group.
  • CONCLUSIONS: Infantile lymphomatoid papulosis is a rare entity clinically manifested as the adult form.
  • [MeSH-minor] Adolescent. Age of Onset. Child. Child, Preschool. Cicatrix / etiology. Clone Cells / pathology. Diagnosis, Differential. Disease Progression. Female. Humans. Lymphoma, T-Cell, Cutaneous / diagnosis. Male. Pigmentation Disorders / etiology. Pityriasis Lichenoides / complications. Remission, Spontaneous. Retrospective Studies. Skin Pigmentation

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20965012.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  •  go-up   go-down


70. Seute T, Leffers P, ten Velde GP, Twijnstra A: Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI). Cancer; 2008 Apr 15;112(8):1827-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of brain metastases from small cell lung cancer: consequences of changing imaging techniques (CT versus MRI).
  • BACKGROUND: The aims of this study were to show 1) the effect of changing from computed tomography (CT) to magnetic resonance imaging (MRI) on the prevalence of detected brain metastases (BM) in patients with newly diagnosed small cell lung cancer (SCLC);.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Small Cell / secondary. Lung Neoplasms / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation / statistics & numerical data. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Neurologic Examination. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Survival Rate


71. Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, Maeda Y, Horikawa K, Okada M, Ohtake S, Yagasaki F, Matsumoto T, Kimura Y, Shinagawa K, Iwanaga M, Miyazaki Y, Ohno R, Naoe T: Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol; 2007 Mar;78(3):213-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome.
  • BACKGROUND: Even after the introduction of all-trans retinoic acid (ATRA), early hemorrhagic death remains a major cause of remission induction failure for acute promyelocytic leukemia (APL).
  • Results were analyzed for 279 patients enrolled in the APL97 study conducted by the Japan Adult Leukemia Study Group (JALSG).
  • Risk factor analysis identified three pretreatment variables associated with severe hemorrhage: initial fibrinogen level, white blood cell count, and performance status.
  • [MeSH-major] Hemorrhage / etiology. Hemorrhage / pathology. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17241371.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


72. Memeo L, Jhang J, Hibshoosh H, Green PH, Rotterdam H, Bhagat G: Duodenal intraepithelial lymphocytosis with normal villous architecture: common occurrence in H. pylori gastritis. Mod Pathol; 2005 Aug;18(8):1134-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Significant differences in the intraepithelial lymphocyte counts between patients with H. pylori gastritis and the comparison group were seen for all three T-cell antigens (P<0.001 for CD3 and CD8 and P<0.002 for TIA-1).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD3 / analysis. Antigens, CD8 / analysis. Female. Gastric Mucosa / microbiology. Gastric Mucosa / pathology. Gastritis / microbiology. Gastritis / pathology. Helicobacter Infections / microbiology. Helicobacter Infections / pathology. Helicobacter pylori / growth & development. Helicobacter pylori / immunology. Humans. Immunohistochemistry. Lymphocyte Count. Lymphocytes / chemistry. Lymphocytes / pathology. Male. Middle Aged. Poly(A)-Binding Proteins. Prospective Studies. Proteins / analysis. RNA-Binding Proteins

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803187.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD8; 0 / Poly(A)-Binding Proteins; 0 / Proteins; 0 / RNA-Binding Proteins; 0 / TIA1 protein, human
  •  go-up   go-down


73. Deviche P, Cortez L: Androgen control of immunocompetence in the male house finch, Carpodacus mexicanus Müller. J Exp Biol; 2005 Apr;208(Pt 7):1287-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To investigate this question, adult males house finches, Carpodacus mexicanus, were exposed to short days and chronically treated with T-filled (T males; N=10) or empty (C males; N=10) Silastic capsules.
  • To study cell-mediated immunity, we measured the local inflammatory response to an injection of phytohemaglutinin (PHA).
  • Thus, T and C males mounted similar humoral and cell-mediated immune responses, but T treatment compromised maintenance of these responses.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. POLYDIMETHYLSILOXANES .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15781889.001).
  • [ISSN] 0022-0949
  • [Journal-full-title] The Journal of experimental biology
  • [ISO-abbreviation] J. Exp. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Dimethylpolysiloxanes; 0 / Phytohemagglutinins; 0 / Silicones; 3XMK78S47O / Testosterone; 63148-62-9 / baysilon
  •  go-up   go-down


74. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E, Fry W, Bethune D, Ayoub J, Ding K, Seymour L, Graham B, Tsao MS, Gandara D, Kesler K, Demmy T, Shepherd F, National Cancer Institute of Canada Clinical Trials Group, National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med; 2005 Jun 23;352(25):2589-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
  • BACKGROUND: We undertook to determine whether adjuvant vinorelbine plus cisplatin prolongs overall survival among patients with completely resected early-stage non-small-cell lung cancer.
  • METHODS: We randomly assigned patients with completely resected stage IB or stage II non-small-cell lung cancer to vinorelbine plus cisplatin or to observation.
  • CONCLUSIONS: Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Massachusetts Medical Society.
  • [CommentIn] Future Oncol. 2005 Oct;1(5):619-23 [16556038.001]
  • [CommentIn] N Engl J Med. 2005 Jun 23;352(25):2640-2 [15972872.001]
  • [CommentIn] N Engl J Med. 2005 Oct 6;353(14):1523-4; author reply 1523-4 [16207858.001]
  • (PMID = 15972865.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04326; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


75. Fauquier T, Rizzoti K, Dattani M, Lovell-Badge R, Robinson IC: SOX2-expressing progenitor cells generate all of the major cell types in the adult mouse pituitary gland. Proc Natl Acad Sci U S A; 2008 Feb 26;105(8):2907-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SOX2-expressing progenitor cells generate all of the major cell types in the adult mouse pituitary gland.
  • The pituitary gland adapts the proportion of each of its endocrine cell types to meet differing hormonal demands throughout life.
  • There is circumstantial evidence that multipotent adult progenitor cells contribute to this plasticity, but these cells have not been identified.
  • Here, we describe a small (<0.05%) population of progenitor cells in the adult pituitary gland.
  • We show that these cells express SOX2, a marker of several early embryonic progenitor and stem cell types, and form "pituispheres" in culture, which can grow, form secondary spheres, and differentiate to all of the pituitary endocrine cell types, as well as folliculostellate cells.
  • Cells expressing SOX2 and E-cadherin are found throughout Rathke's pouch (RP) in embryos but persist in the adult gland, mostly in a narrow zone lining the pituitary cleft, but also are scattered throughout the pituitary.
  • However, unlike in embryonic RP, most of these SOX2(+) cells in the adult gland also express SOX9 and S100.
  • We suggest that this SOX2(+)/SOX9(+) population represents transit-amplifying cells, whereas the SOX2(+)/SOX9(-) cells we identify are multipotent progenitor/stem cells persisting in the adult pituitary.
  • [MeSH-major] Cell Differentiation / physiology. DNA-Binding Proteins / metabolism. HMGB Proteins / metabolism. Pituitary Gland / cytology. Stem Cells / cytology. Transcription Factors / metabolism


76. Ngamkiatphaisan S, Sriratanaban J, Kamolratanakul P, Intragumtornchai T, Noppakun N, Jongudomsuk P: Cost analysis of hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia at King Chulalongkorn Memorial Hospital. J Med Assoc Thai; 2007 Dec;90(12):2565-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost analysis of hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia at King Chulalongkorn Memorial Hospital.
  • The purpose of the study was to analyze the first-year cost ofhematopoietic stem cell transplantation (HSCT) program for the treatment of adult patients with acute myeloid leukemia (AML) at King Chulalongkorn Memorial Hospital (KCMH).
  • The present retrospective study was carried out on 67 AML patients treated with bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT) at KCMH during the period of 1994 to 2005.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / economics. Leukemia, Myeloid, Acute / therapy. Treatment Outcome
  • [MeSH-minor] Adolescent. Adult. Cost-Benefit Analysis. Female. Hospitals, Public. Humans. Male. Middle Aged. Retrospective Studies. Thailand


77. Gokdemir G, Argon A, Sakiz D, Argon D, Köşlü A: Granulomatous slack skin: report of a case with response to electron beam therapy. Med Oncol; 2008;25(2):178-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulomatous slack skin (GSS) is a rare form of cutaneous T-cell lymphoma, closely related to mycosis fungoides.
  • Histologically, a dense atypical lymphoid cell infiltration with numerous multinucleated giant cells and elastolysis was observed.
  • T-cell receptor gene rearrangement was detected in skin lesions.
  • This case report supports that GSS is an indolent variant of mycosis fungoides due to clinical, histological and T-cell gene rearrangement results.
  • [MeSH-major] Electrons / therapeutic use. Lymphoma, T-Cell, Cutaneous / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Humans. Male

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2003 Oct;123(2):297-304 [14531912.001]
  • [Cites] Am J Dermatopathol. 1999 Apr;21(2):156-60 [10218676.001]
  • [Cites] Am J Clin Dermatol. 2007;8(1):51-4 [17298108.001]
  • [Cites] Dermatology. 1996;192(3):288-90 [8726653.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Jul;18(4):397-415 [15196152.001]
  • [Cites] Dermatology. 2003;206(4):393-7 [12771496.001]
  • [Cites] Br J Dermatol. 2005 Nov;153(5):874-80 [16225594.001]
  • [Cites] Br J Dermatol. 2002 Nov;147(5):998-1002 [12410714.001]
  • [Cites] Arch Dermatol. 1992 Apr;128(4):562-3 [1316105.001]
  • [Cites] Blood. 1997 Jul 1;90(1):354-71 [9207472.001]
  • [Cites] J Am Acad Dermatol. 2004 Feb;50(2 Suppl):S4-8 [14726855.001]
  • [Cites] Br J Dermatol. 2000 Feb;142(2):353-7 [10730774.001]
  • [Cites] Br J Dermatol. 1994 Aug;131(2):275-9 [7917995.001]
  • [Cites] Haematologica. 2007 Jun;92(6):784-94 [17550851.001]
  • [Cites] Dermatol Clin. 1994 Apr;12(2):375-89 [8045049.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Jan;128(1):50-4 [11862472.001]
  • [Cites] Am J Surg Pathol. 1988 Feb;12(2):83-95 [3257655.001]
  • [Cites] Acta Derm Venereol. 2001 Jan-Feb;81(1):42-4 [11411914.001]
  • [Cites] Int J Dermatol. 2000 May;39(5):374-6 [10849132.001]
  • (PMID = 17968684.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Williams G, Foyle A, White D, Greer W, Burrell S, Couban S: Intravascular T-cell lymphoma with bowel involvement: case report and literature review. Am J Hematol; 2005 Mar;78(3):207-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular T-cell lymphoma with bowel involvement: case report and literature review.
  • Most cases of IVL are of B-cell immunophenotype; fewer than 15 cases of T-cell IVL have been reported.
  • A 23-year-old male presented with acute abdominal pain, fever, and tender lower abdomen.
  • While visceral involvement with IVL is common at autopsy, IVL presenting as an acute abdomen in an immunocompetent patient has not previously been described.
  • Among the 15 cases of T-cell IVL reported in the literature, only two occurred in people under age 30.
  • Given the rarity of T-cell IVL, it is remarkable that three cases of T-cell IVL have been diagnosed at our institution during a 10-year period.
  • [MeSH-major] Colon / pathology. Lymphoma, T-Cell / pathology. Vascular Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy. Colostomy. Female. Humans. Ileostomy. Intestinal Mucosa / blood supply. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726592.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Donmez A, Cagirgan S, Tombuloglu M: Short-term femoral venous dialysis catheters for autologous peripheral blood progenitor cell collection: retrospective evaluation in 276 catheter practice from a single center. Transfus Apher Sci; 2007 Oct;37(2):165-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term femoral venous dialysis catheters for autologous peripheral blood progenitor cell collection: retrospective evaluation in 276 catheter practice from a single center.
  • [MeSH-major] Catheterization, Central Venous / instrumentation. Catheterization, Central Venous / methods. Femoral Vein. Leukapheresis / instrumentation. Leukapheresis / methods. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Aged. Ecchymosis / etiology. Female. Hematoma / etiology. Hematopoietic Stem Cell Mobilization / adverse effects. Hematopoietic Stem Cell Mobilization / methods. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962077.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


80. Abdeen SH: Immune events associated with protection in C57BL/6 mice immunized with anti-idiotypic antibodies mimicking protective antigens shared between gamma-irradiated cercariae vaccine and human resistance model of Schistosoma haematobium. Egypt J Immunol; 2010;17(2):105-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-idiotypic antibodies (Ab2) were purified from sera of New Zealand white rabbits multiply immunized with gamma-irradiated cercariae of S. haematobium, using adult worm specific idiotypes (Ab1) purified from sera of subjects resistant to reinfection.
  • Results showed an increase of splenic T cell expression of intercellular adhesion molecule-1 (ICAM-1) and very late antigen-4 (VLA-4) upon immunization (average % stimulated cells 54.9 vs. 20.4, P < 0.05 for ICAM-1 and 31.1 vs. 6.6, P < 0.01 for VLA-4) and challenge, especially at day 6 (83.5 vs. 45.6, P < 0.01) for ICAM-1 and day 10 (50.4 vs. 20.8, P < 0.05) for VLA-4.
  • Moreover, sera of Ab2-immunized mice exhibited an anti-anti-ids (Ab3) reactivity against antigens of approximate molecular weight 40, 80 and 160 kDa of adult worms, which were also recognized by Ab1.

  • MedlinePlus Health Information. consumer health - Immunization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23082491.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Integrin alpha4beta1; 0 / Vaccines; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


81. Piro CC, Crossno CL, Collier A, Ho R, Koyama T, Frangoul H: Initial vancomycin dosing in pediatric oncology and stem cell transplant patients. J Pediatr Hematol Oncol; 2009 Jan;31(1):3-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial vancomycin dosing in pediatric oncology and stem cell transplant patients.
  • BACKGROUND: Gram-positive bacteremia is a common infection in pediatric oncology and stem cell transplant (SCT) patients requiring therapy with vancomycin.
  • [MeSH-major] Anti-Bacterial Agents / administration & dosage. Bacteremia / drug therapy. Leukemia / therapy. Stem Cell Transplantation. Vancomycin / administration & dosage
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Dose-Response Relationship, Drug. Humans. Infant. Retrospective Studies. Transplantation, Homologous. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vancomycin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125078.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 6Q205EH1VU / Vancomycin
  •  go-up   go-down


82. von Hentig N, Babacan E, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, Haberl A: The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother; 2008 Sep;62(3):579-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
  • Geometric mean (GM; ANOVA) of minimum and maximum plasma drug concentrations (C(min) and C(max)), area under the concentration-time curve (AUC) and total clearance (CL(total)) were compared between the sexes and correlated to demographic (age, gender and ethnicity), physiological (weight and body mass index) and clinical (CD4+ cell count, HIV-RNA, co-medication and hepatitis serology) co-factors.
  • [MeSH-minor] Adult. Area Under Curve. Atazanavir Sulfate. Chromatography, High Pressure Liquid. Female. Humans. Male. Metabolic Clearance Rate. Middle Aged. Outpatients. Plasma / chemistry. Tandem Mass Spectrometry

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477709.001).
  • [ISSN] 1460-2091
  • [Journal-full-title] The Journal of antimicrobial chemotherapy
  • [ISO-abbreviation] J. Antimicrob. Chemother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HIV Protease Inhibitors; 0 / Oligopeptides; 0 / Pyridines; 4MT4VIE29P / Atazanavir Sulfate; O3J8G9O825 / Ritonavir
  •  go-up   go-down


83. Hałatek T, Trzcinka-Ochocka M, Matczak W, Gruchała J: Serum Clara cell protein as an indicator of pulmonary impairment in occupational exposure at aluminum foundry. Int J Occup Med Environ Health; 2006;19(4):211-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum Clara cell protein as an indicator of pulmonary impairment in occupational exposure at aluminum foundry.
  • The measurement of serum anti-inflammatory Clara cell protein (CC16) was employed as a peripheral marker of the lung epithelium function.
  • [MeSH-minor] Adult. Biomarkers / blood. Dust / analysis. Environmental Monitoring / methods. Forced Expiratory Volume. Humans. Lung Diseases / etiology. Male. Maximal Midexpiratory Flow Rate. Middle Aged. Spirometry

  • MedlinePlus Health Information. consumer health - Indoor Air Pollution.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. ALUMINUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17402216.001).
  • [ISSN] 1232-1087
  • [Journal-full-title] International journal of occupational medicine and environmental health
  • [ISO-abbreviation] Int J Occup Med Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Biomarkers; 0 / Dust; 0 / SCGB1A1 protein, human; 9060-09-7 / Uteroglobin; CPD4NFA903 / Aluminum
  •  go-up   go-down


84. George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K: Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis; 2010 Aug 1;12(4):322-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
  • Between January 2001 and June 2008, 315 adult patients (median age 43 years, range 16-65) including 203 males and 112 females undergoing hematopoietic stem cell transplantation (HSCT) had serial monitoring for cytomegalovirus (CMV) followed by initiation of preemptive therapy.
  • T-cell depletion with anti-thymocyte globulin or alemtuzumab was used in 35%.
  • Other significant risk factors identified included use of alemtuzumab during conditioning (P=0.03), RIC transplants (P=0.06), and the presence of acute graft-versus-host disease (GVHD) (P<0.0001).
  • On a multivariate analysis, CMV serostatus, RIC transplants, and acute GVHD remained independent predictors of CMV reactivation.
  • [MeSH-major] Antibodies, Viral / blood. Cytomegalovirus / physiology. Cytomegalovirus Infections / prevention & control. Cytomegalovirus Infections / virology. Hematopoietic Stem Cell Transplantation / adverse effects. Tissue Donors. Transplantation, Homologous / adverse effects. Virus Activation
  • [MeSH-minor] Adolescent. Adult. Aged. Antiviral Agents / administration & dosage. Antiviral Agents / therapeutic use. Chemoprevention. Female. Humans. Male. Middle Aged. Population Surveillance / methods. Risk Factors. Transplantation Conditioning. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20487414.001).
  • [ISSN] 1399-3062
  • [Journal-full-title] Transplant infectious disease : an official journal of the Transplantation Society
  • [ISO-abbreviation] Transpl Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antiviral Agents
  •  go-up   go-down


85. Baumhoer D, Tzankov A, Dirnhofer S, Tornillo L, Terracciano LM: Patterns of liver infiltration in lymphoproliferative disease. Histopathology; 2008 Jul;53(1):81-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: In equivocal cases, additional immunohistochemical and molecular pathology analyses were performed to differentiate between neoplastic and reactive cell infiltrates and to classify the lymphoma subtypes.
  • Diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukaemia (CLL), Hodgkin's lymphoma (HL) and Burkitt lymphoma (BL) were the most prevalent subtypes in our series, which included 14 different lymphoma entities in total.
  • Interestingly, distinct lymphoma entities, particularly marginal zone B-cell lymphomas (MZL) and HL, commonly revealed lympho-epithelial lesions of bile ducts, which were observed in 10% of all investigated cases.
  • Four cases, initially interpreted as T-cell lymphomas, proved to be reactive T-cell lesions.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Child. Clone Cells. DNA, Neoplasm / analysis. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor / genetics. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540976.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


86. O'Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, Bassing CH, Alt FW, Kelliher M, Look AT: Activating Notch1 mutations in mouse models of T-ALL. Blood; 2006 Jan 15;107(2):781-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have demonstrated that most patients with T-cell acute lymphocytic leukemia (T-ALL) have activating mutations in NOTCH1.
  • We sequenced the heterodimerization domain and the PEST domain of Notch1 in our mouse model of TAL1-induced leukemia and found that 74% of the tumors harbor activating mutations in Notch1.
  • Cell lines derived from these tumors undergo G(0)/G(1) arrest and apoptosis when treated with a gamma-secretase inhibitor.
  • [MeSH-major] Disease Models, Animal. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma / genetics. Mutation / genetics. Receptor, Notch1 / genetics. Thymus Neoplasms / genetics
  • [MeSH-minor] Amyloid Precursor Protein Secretases. Animals. Apoptosis. Aspartic Acid Endopeptidases. Basic Helix-Loop-Helix Transcription Factors / genetics. Basic Helix-Loop-Helix Transcription Factors / physiology. DNA-Binding Proteins / genetics. DNA-Binding Proteins / physiology. Endopeptidases / chemistry. Enzyme Inhibitors / pharmacology. Female. G0 Phase. G1 Phase. Histones / genetics. Histones / physiology. Humans. Male. Mice. Mice, Transgenic. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / physiology. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / physiology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):3831-42 [10805726.001]
  • [Cites] Oncogene. 2006 May 18;25(21):3023-31 [16407836.001]
  • [Cites] Immunity. 2000 Jul;13(1):73-84 [10933396.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1906-13 [10961893.001]
  • [Cites] J Virol. 2000 Oct;74(20):9786-91 [11000255.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Science. 2002 May 3;296(5569):922-7 [11934988.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8173-8 [12034884.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cell. 2003 Aug 8;114(3):359-70 [12914700.001]
  • [Cites] Cell. 2003 Aug 8;114(3):371-83 [12914701.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2593-6 [12816868.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4):274-80 [14582078.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1909-11 [14604958.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):587-96 [15193261.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Cell. 1992 Mar 6;68(5):855-67 [1547487.001]
  • [Cites] Cell. 1996 Apr 5;85(1):27-37 [8620534.001]
  • [Cites] EMBO J. 1996 Oct 1;15(19):5160-6 [8895560.001]
  • [Cites] Oncogene. 1998 Jan 29;16(4):517-22 [9484841.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 16166587.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096899
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Enzyme Inhibitors; 0 / H2AX protein, mouse; 0 / Histones; 0 / NOTCH1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Rag2 protein, mouse; 0 / Receptor, Notch1; 0 / Tal1 protein, mouse; 0 / Tumor Suppressor Protein p53; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.4.- / Endopeptidases; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.46 / BACE1 protein, human; EC 3.4.23.46 / Bace1 protein, mouse
  • [Other-IDs] NLM/ PMC1895623
  •  go-up   go-down


87. Matsumoto S, Iwata H, Shirahashi K, Saio M, Umeda Y, Marui T, Ishida N, Kimura M, Sugimoto T, Manabe H, Takemura H: Suppression of right ventricular hypertrophy after extensive pulmonary resection in rats by granulocyte colony-stimulating factor. J Surg Res; 2010 Aug;162(2):153-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Adult rats were divided into four groups:.
  • At postoperative day 21, weight ratio of the right ventricular to the left ventricle plus septum (RV/LV+S, indicator of right ventricular hypertrophy) were measured, and a histopathological study was conducted to determine percentage wall thickness of peripheral pulmonary arteries and proliferating cell nuclear antigen labeling index (indicator of oxidative DNA damage) of right ventricles.
  • Incidence of proliferating cell nuclear antigen positive nuclei for Group S was 1.07% +/- 0.49%, significantly smaller than that for Group L (13.77% +/- 5.87%).
  • G-CSF significantly reduced the incidence of proliferating cell nuclear antigen positive nuclei (LG10, 4.04% +/- 2.14%; LG100, 3.18% +/- 1.66%).
  • [MeSH-minor] Animals. Anterior Temporal Lobectomy / mortality. Hemoglobins / drug effects. Hypertrophy, Left Ventricular / drug therapy. Hypertrophy, Left Ventricular / etiology. Hypertrophy, Left Ventricular / surgery. Leukocytes / drug effects. Leukocytes / physiology. Male. Muscle Cells / physiology. Proliferating Cell Nuclear Antigen / metabolism. Pulmonary Artery / pathology. Rats. Rats, Sprague-Dawley. Thoracotomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 19457496.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Proliferating Cell Nuclear Antigen; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


88. Jeang KT: Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction? Oncotarget; 2010 Oct;1(6):453-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction?
  • The mechanism of HTLV-1 transformation of cells to Adult T cell leukemia (ATL) remains not fully understood.
  • [MeSH-minor] Adult. HTLV-I Infections / genetics. HTLV-I Infections / virology. Humans

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Aug;3(8):448-57 [16894390.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Nat Med. 2007 May;13(5):527-8 [17479090.001]
  • [Cites] J Cell Biochem. 2007 Oct 15;102(3):531-8 [17661351.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16170-5 [17911264.001]
  • [Cites] Retrovirology. 2007;4:82 [18036240.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8976-85 [18974142.001]
  • [Cites] Retrovirology. 2008;5:100 [19014482.001]
  • [Cites] Blood. 2009 May 14;113(20):4914-7 [19246560.001]
  • [Cites] Virus Res. 2009 Aug;143(2):195-208 [19540281.001]
  • [Cites] Nat Rev Genet. 2009 Oct;10(10):704-14 [19763153.001]
  • [Cites] Genes Dev. 2009 Dec 1;23(23):2700-4 [19903759.001]
  • [Cites] Retrovirology. 2009;6:117 [20017952.001]
  • [Cites] Retrovirology. 2010;7:17 [20222966.001]
  • [Cites] J Biol Chem. 2010 Aug 6;285(32):24707-16 [20529860.001]
  • [Cites] Mol Aspects Med. 2010 Oct;31(5):367-82 [20600265.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):559-67 [14991578.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Nature. 1990 Nov 15;348(6298):245-8 [2146511.001]
  • [Cites] Int Immunol. 1991 Aug;3(8):761-7 [1911545.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [7862633.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):6698-703 [9506967.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] J Virol. 1999 Jun;73(6):4856-65 [10233947.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Retrovirology. 2005;2:17 [15743526.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5931-7 [16155600.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • (PMID = 21311101.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AI001023-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS242806; NLM/ PMC3058865
  •  go-up   go-down


89. Rodríguez-Pinilla SM, Atienza L, Murillo C, Pérez-Rodríguez A, Montes-Moreno S, Roncador G, Pérez-Seoane C, Domínguez P, Camacho FI, Piris MA: Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol; 2008 Dec;32(12):1787-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T-cell lymphoma with follicular T-cell markers.
  • INTRODUCTION: Peripheral T-cell lymphomas (PTCLs) in western countries are uncommon tumors with unfavorable prognosis.
  • They may be subclassified as anaplastic large-cell lymphomas (ALCLs), angioimmunoblastic-T-cell lymphomas (AITLs), or unspecified peripheral T-cell lymphomas (PTCLs-U).
  • The aim of this study was to establish whether other PTCL subgroups also express TFH cell markers.
  • PD-1-positive cases, which did not fulfill all the criteria for AITL, were further evaluated in whole-tissue sections for another 12 immunohistochemical markers, including the TFH cell markers CXCL13, CD10, and BCL6.
  • Clonal Ig and T-cell receptor rearrangements and Epstein-Barr virus-encoded RNA expression were also evaluated.
  • All cases expressed at least 2 TFH cell markers.
  • CONCLUSIONS: TFH cell markers, especially PD-1, were expressed in a subset of PTCLs not classified as AITL, although most of them shared some morphologic features with AITL.
  • [MeSH-major] Antigens, CD / biosynthesis. Apoptosis Regulatory Proteins / biosynthesis. Biomarkers / analysis. Lymphoma, T-Cell, Peripheral / classification. Lymphoma, T-Cell, Peripheral / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemokine CXCL13 / biosynthesis. Female. Gene Rearrangement, T-Lymphocyte. Humans. Immunohistochemistry. In Situ Hybridization. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Middle Aged. Neprilysin / biosynthesis. Programmed Cell Death 1 Receptor. Proto-Oncogene Proteins / biosynthesis. Repressor Proteins / biosynthesis. T-Lymphocytes, Helper-Inducer / metabolism. T-Lymphocytes, Helper-Inducer / pathology. Tissue Array Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18779728.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / BCOR protein, human; 0 / Biomarkers; 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / Proto-Oncogene Proteins; 0 / Repressor Proteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


90. Chen J, Su X, Zhang Y, Wang S, Shao L, Wu J, Wang F, Zhang S, Wang J, Weng X, Wang H, Zhang W: Novel recombinant RD2- and RD11-encoded Mycobacterium tuberculosis antigens are potential candidates for diagnosis of tuberculosis infections in BCG-vaccinated individuals. Microbes Infect; 2009 Sep;11(10-11):876-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All six purified recombinant proteins could distinguish tuberculosis (TB) patients and latent TB infected subjects (LTBI), or called subclinical TB infection, from BCG-vaccinated healthy controls by T-cell IFN-gamma releasing ELISPOT.

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19467342.001).
  • [ISSN] 1769-714X
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / BCG Vaccine; 0 / Recombinant Proteins; 144058-44-6 / Mycobacterium tuberculosis antigens; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


91. Vrisekoop N, van Gent R, de Boer AB, Otto SA, Borleffs JC, Steingrover R, Prins JM, Kuijpers TW, Wolfs TF, Geelen SP, Vulto I, Lansdorp P, Tesselaar K, Borghans JA, Miedema F: Restoration of the CD4 T cell compartment after long-term highly active antiretroviral therapy without phenotypical signs of accelerated immunological aging. J Immunol; 2008 Jul 15;181(2):1573-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restoration of the CD4 T cell compartment after long-term highly active antiretroviral therapy without phenotypical signs of accelerated immunological aging.
  • It remains uncertain whether full T cell reconstitution can be established in HIV-infected children and adults with long-term sustained virological control by highly active antiretroviral therapy (HAART).
  • In this study, we comprehensively analyzed various phenotypical markers of CD4 T cell recovery.
  • In addition to measuring T cell activation and proliferation markers, CD4 T cell generation and aging of the CD4 T cell compartment were assessed by measuring TCR excision circles and the fraction of CD31-expressing naive CD4 T cells.
  • In all children and in adults with relatively high CD4 T cell counts at start of therapy (>200 cells/microl), total CD4 T cell numbers normalized within 1 year of therapy.
  • After long-term HAART (4.4-9.6 years), naive CD4 T cell counts had normalized in both groups.
  • Although in adults with low baseline CD4 T cell counts (<200 cells/microl) total CD4 T cell numbers normalized eventually after at least 7 years of HAART, naive CD4 T cell counts had still not recovered.
  • TCR excision circle data showed that thymic T cell production contributed to naive T cell recovery at all ages.
  • The fraction of CD31-expressing naive CD4 T cells was found to be normal, suggesting that the CD4 T cell repertoire was diverse after long-term HAART.
  • Hence, under sustained viral suppression during long-term HAART, the T cell compartment has the potential to fully recover by generating new naive T cells both in children and in adults with high baseline CD4 T cells counts.
  • Irrespective of baseline CD4 T cell counts, reconstitution occurred without a significant effect on T cell aging as reflected by markers for replicative history.
  • [MeSH-minor] Adolescent. Adult. CD4 Lymphocyte Count. Child. Child, Preschool. HIV-1. Humans. Infant. Lymphocyte Activation. Middle Aged. T-Lymphocyte Subsets / immunology

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18606713.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Ki-67 Antigen
  •  go-up   go-down


92. Deenadayalan A, Heaslip D, Rajendiran AA, Velayudham BV, Frederick S, Yang HL, Dobos K, Belisle JT, Raja A: Immunoproteomic identification of human T cell antigens of Mycobacterium tuberculosis that differentiate healthy contacts from tuberculosis patients. Mol Cell Proteomics; 2010 Mar;9(3):538-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoproteomic identification of human T cell antigens of Mycobacterium tuberculosis that differentiate healthy contacts from tuberculosis patients.
  • To identify the antigens of M. tuberculosis that differentiated between tuberculosis (TB) patients and healthy contacts based on T cell reactivity, the culture filtrate of in vitro grown M. tuberculosis was fractionated by two-dimensional liquid phase electrophoresis and tested for the ability to stimulate T cells in a whole blood assay.
  • Proteomic characterization of the 105 fractions that induced a significant IFN-gamma response in the healthy contacts compared with the TB patients led to the identification of 59 proteins of which 24 represented potentially novel T cell antigens.

  • Genetic Alliance. consumer health - Tuberculosis.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1998 Jun 11;393(6685):537-44 [9634230.001]
  • [Cites] Eur J Immunol. 1998 Dec;28(12):3949-58 [9862331.001]
  • [Cites] Infect Dis Clin North Am. 1999 Mar;13(1):169-85, vii-viii [10198798.001]
  • [Cites] Mol Microbiol. 1999 Sep;33(6):1103-17 [10510226.001]
  • [Cites] Vaccine. 2004 Dec 21;23(6):780-8 [15542202.001]
  • [Cites] J Clin Microbiol. 2005 Jan;43(1):57-65 [15634951.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):467-72 [15626759.001]
  • [Cites] Clin Diagn Lab Immunol. 2005 Feb;12(2):354-8 [15699433.001]
  • [Cites] Int J Tuberc Lung Dis. 2005 Feb;9(2):195-9 [15732740.001]
  • [Cites] Nat Med. 2005 Apr;11(4 Suppl):S33-44 [15812488.001]
  • [Cites] Infect Immun. 2005 Jun;73(6):3547-58 [15908384.001]
  • [Cites] Microbes Infect. 2005 Apr;7(4):776-88 [15823514.001]
  • [Cites] J Clin Microbiol. 2005 Jul;43(7):3185-91 [16000433.001]
  • [Cites] Microbiology. 2005 Jul;151(Pt 7):2411-9 [16000731.001]
  • [Cites] FEMS Microbiol Lett. 2005 Aug 1;249(1):87-94 [16006064.001]
  • [Cites] Infect Immun. 2005 Aug;73(8):4676-83 [16040980.001]
  • [Cites] Nat Rev Immunol. 2005 Aug;5(8):661-7 [16056257.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Sep;49(9):3707-14 [16127044.001]
  • [Cites] Infect Immun. 1999 Nov;67(11):5967-71 [10531255.001]
  • [Cites] Scand J Immunol. 2000 Jan;51(1):79-86 [10632980.001]
  • [Cites] J Clin Microbiol. 2000 Sep;38(9):3285-90 [10970372.001]
  • [Cites] Electrophoresis. 2000 Nov;21(17):3740-56 [11271494.001]
  • [Cites] Infect Immun. 2001 Aug;69(8):4839-45 [11447158.001]
  • [Cites] Proteomics. 2001 Apr;1(4):574-86 [11681210.001]
  • [Cites] J Clin Microbiol. 2002 Feb;40(2):704-6 [11826002.001]
  • [Cites] J Bacteriol. 2002 Jul;184(13):3485-91 [12057942.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Infect Immun. 2003 Jan;71(1):483-93 [12496199.001]
  • [Cites] Infect Immun. 2003 Feb;71(2):708-16 [12540549.001]
  • [Cites] Infect Immun. 2003 Apr;71(4):1929-37 [12654810.001]
  • [Cites] Infect Immun. 2003 Jul;71(7):3927-36 [12819079.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Sep;47(9):2903-13 [12936993.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Mol Cell Proteomics. 2003 Dec;2(12):1284-96 [14532352.001]
  • [Cites] Infect Immun. 2004 Jan;72(1):381-8 [14688119.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):314-9 [14695899.001]
  • [Cites] Scand J Immunol. 2004 Jan;59(1):16-24 [14723617.001]
  • [Cites] Mol Cell Proteomics. 2004 Jan;3(1):24-42 [14557599.001]
  • [Cites] Int J Med Microbiol. 2003 Dec;293(6):391-401 [14760970.001]
  • [Cites] FEMS Microbiol Lett. 2004 Mar 12;232(1):51-9 [15019734.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12652-7 [15314217.001]
  • [Cites] Infect Immun. 2004 Nov;72(11):6471-9 [15501778.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] J Immunol Methods. 1987 Apr 2;98(1):5-10 [3104476.001]
  • [Cites] Rev Infect Dis. 1989 Mar-Apr;11 Suppl 2:S353-9 [2652252.001]
  • [Cites] Infect Immun. 1991 Jan;59(1):372-82 [1898899.001]
  • [Cites] Infect Immun. 1991 Feb;59(2):665-70 [1898911.001]
  • [Cites] Anal Biochem. 1992 May 15;203(1):173-9 [1524213.001]
  • [Cites] J Immunol Methods. 1993 May 5;161(1):29-39 [8486927.001]
  • [Cites] J Exp Med. 1993 Dec 1;178(6):2249-54 [7504064.001]
  • [Cites] Infect Immun. 1995 Mar;63(3):954-60 [7868268.001]
  • [Cites] Infect Immun. 1995 Apr;63(4):1491-7 [7890415.001]
  • [Cites] Anal Biochem. 1995 Jan 1;224(1):451-5 [7710111.001]
  • [Cites] Vet Immunol Immunopathol. 1995 Sep;48(1-2):183-90 [8533313.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Infect Immun. 1996 Nov;64(11):4834-7 [8890247.001]
  • [Cites] N Engl J Med. 1996 Dec 26;335(26):1956-61 [8960475.001]
  • [Cites] Infect Immun. 1998 Jan;66(1):176-80 [9423855.001]
  • [Cites] Lancet. 2005 Oct 22-28;366(9495):1414-6 [16243075.001]
  • [Cites] Vaccine. 2005 Dec 1;23(48-49):5655-65 [16157425.001]
  • [Cites] Tuberculosis (Edinb). 2005 Sep-Nov;85(5-6):385-94 [16253564.001]
  • [Cites] J Bacteriol. 2006 Feb;188(4):1364-72 [16452418.001]
  • [Cites] Mol Microbiol. 2006 May;60(4):999-1013 [16677310.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):422-9 [16785538.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11346-51 [16844784.001]
  • [Cites] Nat Rev Immunol. 2006 Sep;6(9):699-704 [16917508.001]
  • [Cites] Microbiol Mol Biol Rev. 2006 Sep;70(3):755-88 [16959968.001]
  • [Cites] Science. 2006 Oct 20;314(5798):454-8 [17053144.001]
  • [Cites] Lancet. 2006 Dec 16;368(9553):2142-54 [17174706.001]
  • [Cites] Infect Immun. 2007 Jan;75(1):527-30 [17088357.001]
  • [Cites] Mem Inst Oswaldo Cruz. 2006 Dec;101(8):857-61 [17293979.001]
  • [Cites] Proteomics. 2007 May;7(10):1702-18 [17443846.001]
  • [Cites] Infect Immun. 2007 Jun;75(6):2914-21 [17387166.001]
  • [Cites] Chest. 2007 Jun;131(6):1898-906 [17565023.001]
  • [Cites] Swiss Med Wkly. 2007 Jun 30;137(25-26):357-62 [17629798.001]
  • [Cites] J Cell Sci. 2007 Aug 15;120(Pt 16):2796-806 [17652161.001]
  • [Cites] Proteomics. 2007 Sep;7(18):3332-41 [17849409.001]
  • [Cites] PLoS One. 2008;3(1):e1403 [18167562.001]
  • [Cites] Scand J Immunol. 2008 Mar;67(3):245-52 [18208443.001]
  • [Cites] Genome Biol. 2007;8(12):R265 [18078514.001]
  • [Cites] PLoS One. 2008;3(4):e1973 [18398483.001]
  • [Cites] Int J Tuberc Lung Dis. 2008 Nov;12(11):1226-34 [18926032.001]
  • (PMID = 20031926.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / HHSN266200400091C; United States / PHS HHS / / HHSN266200400091C
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Tumor Necrosis Factor-alpha; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2849706
  •  go-up   go-down


93. Skibola CF, Nieters A, Bracci PM, Curry JD, Agana L, Skibola DR, Hubbard A, Becker N, Smith MT, Holly EA: A functional TNFRSF5 gene variant is associated with risk of lymphoma. Blood; 2008 Apr 15;111(8):4348-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We hypothesized that single nucleotide polymorphisms (SNPs) in TNFRSF5 and TNFSF5 encoding the CD40 and CD154 proteins, respectively, influence lymphoma risk, particularly a functional TNFRSF5 SNP (-1C>T, rs1883832) associated with reduced B-cell CD40 expression.
  • Further, dendritic cells from those with -1TT versus -1CC genotypes exhibited lower CD40 cell surface expression.
  • [MeSH-minor] Adult. Aged. CD40 Ligand / genetics. Confidence Intervals. Cytosine. Dendritic Cells / drug effects. Humans. Lipopolysaccharides / pharmacology. Middle Aged. Odds Ratio. Solubility. Thymine

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1991 Oct 25;266(30):19867-70 [1939050.001]
  • [Cites] Heart Vessels. 2005 Nov;20(6):245-50 [16314905.001]
  • [Cites] Eur J Immunol. 1994 Apr;24(4):787-92 [7512028.001]
  • [Cites] Immunity. 1994 Aug;1(5):423-31 [7882172.001]
  • [Cites] Adv Immunol. 1996;63:43-78 [8787629.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3804-9 [10577852.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12614-9 [11675497.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2285-90 [11895757.001]
  • [Cites] Hum Mutat. 2002 May;19(5):479-85 [11968080.001]
  • [Cites] Bioinformatics. 2002 Dec;18(12):1694-5 [12490459.001]
  • [Cites] Thyroid. 2002 Dec;12(12):1129-35 [12593727.001]
  • [Cites] Immunol Rev. 2003 Aug;194:61-76 [12846808.001]
  • [Cites] Am J Epidemiol. 2003 Aug 15;158(4):316-27 [12915497.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32801-9 [12810728.001]
  • [Cites] Immunology. 2003 Sep;110(1):131-40 [12941150.001]
  • [Cites] Blood. 2003 Dec 1;102(12):4099-106 [12893749.001]
  • [Cites] Leuk Res. 2004 Jul;28(7):713-24 [15158093.001]
  • [Cites] Eur J Immunol. 1997 Jun;27(6):1398-405 [9209491.001]
  • [Cites] Br J Haematol. 1998 Jan;100(1):135-41 [9450802.001]
  • [Cites] J Leukoc Biol. 1998 Apr;63(4):418-28 [9544571.001]
  • [Cites] Annu Rev Immunol. 1998;16:111-35 [9597126.001]
  • [Cites] Nature. 1998 Jun 4;393(6684):474-8 [9624003.001]
  • [Cites] Nature. 1998 Jun 4;393(6684):478-80 [9624004.001]
  • [Cites] Nature. 1998 Jun 4;393(6684):480-3 [9624005.001]
  • [Cites] Ann N Y Acad Sci. 2005 Dec;1062:51-60 [16461788.001]
  • [Cites] Cancer. 2006 May 15;106(10):2148-57 [16598754.001]
  • [Cites] Eur J Immunol. 2006 Jul;36(7):1665-73 [16783845.001]
  • [Cites] Cell Immunol. 2006 May;241(1):47-58 [16963006.001]
  • [Cites] Endocr Metab Immune Disord Drug Targets. 2007 Mar;7(1):23-8 [17346201.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4169-76 [17371973.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Apr 15;175(8):775-82 [17255560.001]
  • [Cites] Genes Immun. 2007 Apr;8(3):205-14 [17344890.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4810-5 [17311995.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2007 May-Jun;42(3):113-85 [17562450.001]
  • [Cites] Haematologica. 2007 Jul;92(7):960-9 [17606447.001]
  • [Cites] Am J Public Health. 1998 Dec;88(12):1767-73 [9842372.001]
  • [Cites] J Rheumatol. 1999 Aug;26(8):1676-80 [10451061.001]
  • [Cites] Am J Epidemiol. 1999 Aug 15;150(4):375-89 [10453814.001]
  • [Cites] Endocrinology. 2005 Jun;146(6):2684-91 [15731360.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2391-401 [16214922.001]
  • [Cites] J Cell Biol. 1991 Nov;115(4):887-903 [1955461.001]
  • (PMID = 18287517.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA89745; United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / CA / CA122663; United States / NCI NIH HHS / CA / CA87014; United States / NCI NIH HHS / CA / R01 CA122663; United States / NCI NIH HHS / CA / R01 CA087014; United States / NCI NIH HHS / CA / CA104862; United States / NCI NIH HHS / CA / R01 CA045614; United States / NCI NIH HHS / CA / R03 CA089745
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / Lipopolysaccharides; 147205-72-9 / CD40 Ligand; 8J337D1HZY / Cytosine; QR26YLT7LT / Thymine
  • [Other-IDs] NLM/ PMC2288730
  •  go-up   go-down


94. Scaruffi P, Stigliani S, Coco S, Valdora F, De Vecchi C, Bonassi S, Tonini GP: Transcribed-ultra conserved region expression profiling from low-input total RNA. BMC Genomics; 2010;11:149
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The recent findings that they are significantly altered in adult chronic lymphocytic leukemias, carcinomas, and pediatric neuroblastomas lead to the hypothesis that UCRs may play a role in tumorigenesis.
  • Direct comparison of non-amplified with amplified cDNA in two neuroblastoma cell lines showed that the amplification approach increases sensitivity and repeatability in T-UCR quantification.
  • This issue is particularly important because studies of transcription regulation are increasingly conducted in small homogeneous samples, such as laser capture microdissected or sorted cell populations.
  • [MeSH-minor] Cell Line. Humans. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction. Sample Size. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 2003 Dec;283(1-2):291-306 [14659920.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2527-8; author reply 2528-31 [14671651.001]
  • [Cites] Science. 2004 May 28;304(5675):1321-5 [15131266.001]
  • [Cites] Bioinformatics. 2004 Aug 4;20 Suppl 1:i40-8 [15262779.001]
  • [Cites] Biotechniques. 2004 Nov;37(5):854-7 [15560142.001]
  • [Cites] BMC Cancer. 2009;9:441 [20003513.001]
  • [Cites] Nature. 2006 May 4;441(7089):87-90 [16625209.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):215-29 [17785203.001]
  • [Cites] Nucleic Acids Res. 2008 Dec;36(21):e143 [18940866.001]
  • [Cites] Clin Chem. 2009 Apr;55(4):611-22 [19246619.001]
  • [Cites] Nucleic Acids Res. 2009 Apr;37(7):2065-9 [19223324.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1973-81 [16123149.001]
  • (PMID = 20199688.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Untranslated
  • [Other-IDs] NLM/ PMC2838852
  •  go-up   go-down


95. Fjaertoft G, Håkansson L, Foucard T, Ewald U, Venge P: CD64 (Fcgamma receptor I) cell surface expression on maturing neutrophils from preterm and term newborn infants. Acta Paediatr; 2005 Mar;94(3):295-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD64 (Fcgamma receptor I) cell surface expression on maturing neutrophils from preterm and term newborn infants.
  • METHODS: Cell surface expression of CD64 on neutrophils from preterm and term newborn infants and healthy adults was analysed by flow cytometry.
  • [MeSH-minor] Adult. Age Factors. Antigens, CD11b / metabolism. Female. Fetal Membranes, Premature Rupture / metabolism. Flow Cytometry. Humans. Infant, Newborn. Pregnancy

  • MedlinePlus Health Information. consumer health - Premature Babies.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028647.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Receptors, IgG
  •  go-up   go-down


96. Takada M, Shimomura T, Hokari S, Jensik PJ, Cox TC: Larval bullfrog skin expresses ENaC despite having no amiloride-blockable transepithelial Na+ transport. J Comp Physiol B; 2006 May;176(4):287-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using specific PCR primers for adult frog ENaC and RT-PCR, we investigated whether corticoids can induce all three ENaC subunits, and whether this expression of ENaC subunit(s) can be blocked by adding PRL with the corticoids.
  • We found that (1) the sequences of the RT-PCR products obtained using primers for alpha-ENaC were identical between larval and adult skins, (2) the mRNAs for all three ENaC subunits were expressed in larval skin under normal conditions despite no amiloride-blockable Na(+) transport being detectable, (3) all three subunits were expressed in larval skins whether they were cultured with corticoids (amiloride-blockable Na transport present) or with corticoids supplemented with PRL (no amiloride-blockable Na transport present).
  • An antibody against a peptide from the alpha-ENaC of adult bullfrog was localized to the apical cells of both larval and adult skins.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Physiol. 2002 May;119(5):427-42 [11981022.001]
  • [Cites] J Exp Zool. 1997 Oct 15;279(3):220-7 [9379152.001]
  • [Cites] Am J Physiol. 1995 Jan;268(1 Pt 1):C218-26 [7840151.001]
  • [Cites] Physiol Rev. 2002 Jul;82(3):735-67 [12087134.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Sep;281(3):C954-62 [11502572.001]
  • [Cites] Jpn J Physiol. 1985;35(3):525-34 [3877201.001]
  • [Cites] Biochim Biophys Acta. 1998 Mar 6;1370(1):169-74 [9518595.001]
  • [Cites] Am J Physiol. 1992 Oct;263(4 Pt 2):R827-33 [1415795.001]
  • [Cites] Am J Physiol. 1993 Mar;264(3 Pt 1):C552-8 [8460664.001]
  • [Cites] J Comp Physiol B. 2002 Oct;172(7):569-76 [12355225.001]
  • [Cites] Nature. 1994 Feb 3;367(6462):463-7 [8107805.001]
  • [Cites] J Gen Physiol. 1997 Jun;109(6):681-92 [9222895.001]
  • [Cites] Am J Physiol. 1999 Nov;277(5 Pt 2):R1305-12 [10564201.001]
  • [Cites] Nat Genet. 1996 Mar;12(3):325-8 [8589728.001]
  • [Cites] J Exp Biol. 2003 Apr;206(Pt 7):1137-42 [12604573.001]
  • [Cites] Anat Rec. 1946 Jan;94:7-13 [21013391.001]
  • [Cites] J Gen Physiol. 1998 Jun;111(6):825-46 [9607939.001]
  • [Cites] Am J Physiol. 1989 Jan;256(1 Pt 1):C168-74 [2463761.001]
  • [Cites] Am J Physiol. 1996 Oct;271(4 Pt 1):C1059-63 [8897810.001]
  • [Cites] Proc Am Thorac Soc. 2004;1(1):4-9 [16113404.001]
  • [Cites] Biochim Biophys Acta. 1982 Nov 22;692(3):455-61 [6293572.001]
  • [Cites] Am J Physiol. 1979 Jul;237(1):R74-9 [313715.001]
  • [Cites] Dev Biol. 1989 Feb;131(2):337-44 [2463945.001]
  • [Cites] Science. 1965 Jun 18;148(3677):1612-3 [14287607.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Jan;288(1):C141-7 [15355850.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Int Rev Cytol. 1993;145:105-48 [8500980.001]
  • [Cites] Pflugers Arch. 2001 Jul;442(4):534-6 [11510885.001]
  • [Cites] Anat Rec. 1987 Mar;217(3):305-17 [3495206.001]
  • (PMID = 16308722.001).
  • [ISSN] 0174-1578
  • [Journal-full-title] Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology
  • [ISO-abbreviation] J. Comp. Physiol. B, Biochem. Syst. Environ. Physiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies; 0 / Epithelial Sodium Channels; 0 / RNA, Messenger; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2X; 0 / Sodium Channel Blockers; 0 / Sodium Channels; 7DZO8EB0Z3 / Amiloride
  •  go-up   go-down


97. Chen W, Wang J, Wang E, Lu Y, Lau SK, Weiss LM, Huang Q: Detection of clonal lymphoid receptor gene rearrangements in langerhans cell histiocytosis. Am J Surg Pathol; 2010 Jul;34(7):1049-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of clonal lymphoid receptor gene rearrangements in langerhans cell histiocytosis.
  • Langerhans cell histiocytosis (LCH), also known as histiocytosis X, is a rare human disorder characterized by an abnormal accumulation and/or clonal proliferation of Langerhans cells (LCs) in various body organs.
  • To gain a better understanding of the pathogenesis and cellular origin of human LCH, we retrospectively investigated 46 well-characterized LCH cases to detect clonal rearrangements of T-cell receptor gamma gene (TRG@) and immunoglobulin heavy chain and kappa light chain genes (IGH@/IGK@).
  • None (0/46) of the cases had a known history or concurrent B or T-cell lymphoma.
  • Interestingly, of the 14 cases with at least one clonal rearrangement of lymphoid receptor genes, 3 LCH cases were shown to have both TRG@ and IGH@/IGK@ gene rearrangements, but failed to express T-cell or B-cell lineage specific or associated markers, suggesting lineage plasticity or infidelity of the neoplasm.
  • [MeSH-major] Gene Rearrangement, B-Lymphocyte. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor. Histiocytosis, Langerhans-Cell / pathology. Langerhans Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Cell Lineage. Child. Child, Preschool. Clone Cells. DNA, Neoplasm / analysis. Female. Humans. Immunoglobulin Heavy Chains / genetics. Immunoglobulin kappa-Chains / genetics. Immunohistochemistry. Immunophenotyping. Infant. Male. Middle Aged. Receptors, Antigen, T-Cell, gamma-delta / genetics. Retrospective Studies. Young Adult